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ABSTRACT 
High--throughput sequencing has become pervasive in all facets of genomic 
analysis. I developed computational methods to analyze high--throughput 
sequencing data and derive biological conclusions in two research areas — 
transcriptional regulation in mammals and evolution of virus under immune 
pressure. 
To investigate transcriptional regulation, I integrated data from multiple 
experiments performed by the ENCODE consortium. First, my analysis revealed 
that Transcription Factors (TFs) prefer to bind GC--rich, histone--depleted 
regions. By comparing in vivo and in vitro nucleosome dynamics, I observed that 
while histones have an innate preference for binding GC--rich DNA, TF binding 
overrides this preference and produces a negative correlation between GC 
  vii 
content and histone enrichment. In the next project, I found that the binding 
events of multiple TFs co--occur at genomic regions enriched in activating 
histone marks that are typically associated with gene enhancers and promoters, 
suggesting that these regions may be enhancers or have TSS--distal 
transcription. Lastly, I used supervised machine -learning techniques to train 
histone enrichment signals and sequence features to predict transcriptional 
enhancers to be validated in mouse--transgenic assays. 
In a post--clinical trial exploratory analysis of Hepatitis C Virus (HCV), I traced the 
evolutionary path of the envelope proteins E1 and E2 in HCV-infected liver 
transplant patients, in response to a novel antibody. I developed a systematic 
amino acid--level analysis pipeline that quantifies differences in amino acid 
frequencies in each position between two time points. Upon applying this method 
across all positions in the E1/E2 region and comparing pre--liver--transplant and 
post--viral--rebound time points, mutations in two positions emerged as being key 
to antibody evasion. Both these mutations—N415K/D and N417S—were in the 
epitope targeted by the antibody, but surprisingly, did not co--occur. In post--
rebound viral genomes that contain the N417S mutation but retain the wild--type 
variant at 415, N--linked glycosylation of 415 is another possible escape 
mechanism. Using the same analysis pipeline, I also identified additional 
candidate escape mutations outside the epitope, which could be potential 
therapeutic targets.   
  viii 
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1. INTRODUCTION 
Transcriptional Regulation 
 
The genomes of higher-order organisms contain genes—the subset of the DNA 
sequence that is transcribed into RNA and subsequently to proteins, regulated by 
various checkpoints in this pathway(Crick, 1970). The formation of complementary 
RNA copies from a DNA template is called transcription. The combined levels 
of genes that are transcribed into RNA—measured as gene expression—
determine the lineage of a cell, but not independently so. Each type of cell in a 
multicellular organism consists of nearly identical DNA, and yet the functions 
performed vary vastly between cell types—muscle cells have to carry out 
different functions as compared to neuronal cells, for instance. This difference 
between cell types is brought about by altering the expression of genes in a cell-
type-specific manner. This differential expression of genes between cells of 
different lineages is effected by various cellular components acting together on 
the genome in a coordinated manner. These are collectively known as 
“epigenetic” processes(“epi” meaning “above”), and include unwinding of DNA 
around histone proteins leading to more “open” chromatin(John et al., 2011), post-
translational modification of histone proteins around which DNA is 
wound(Bannister & Kouzarides, 2011; Strahl & Allis, 2000; Tessarz & Kouzarides, 
2014), binding of proteins called Transcription Factors(TFs) to DNA to activate or 
repress transcription(Spitz & Furlong, 2012), changes to the 3-dimensional 
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conformation of chromatin(Dekker, Marti-Renom, & Mirny, 2013) and methylation of 
DNA(Smith & Meissner, 2013).  
 
Transcription of genes into RNA is initiated by the binding of RNA Polymerase II 
(Pol II) at Transcription Start Sites (TSSs), which co-occurs with the binding of 
complexes of TFs to their cognate DNA sequences. But in order for TFs to 
recognize and bind DNA, the latter must first be accessible(John et al., 2011). 
DNA is present in the cell as chromatin, whose basic unit is the nucleosome—
146 bases of DNA around an octameric histone protein complex(Kornberg, 1974). 
The rotational conformation of nucleosomes determines the accessibility of TF 
binding motifs encoded in its DNA to their corresponding TFs(Albert et al., 2007). 
The unwinding of DNA is caused by eviction or destabilization of the attached 
histone proteins, thereby exposing the underlying DNA to reveal potential 
sequence motifs for TF binding(Berger, 2007; Clapier & Cairns, 2009).  Increased 
DNA accessibility has been associated with specific post-translational 
modifications of histone proteins(Tessarz & Kouzarides, 2014), such as acetylation 
of histone residues H3K27, H3K9 and H3K56.   
The sequence around a TSS where TFs assemble to initiate transcription—
roughly 1000 bases upstream and downstream of a TSS—is canonically known 
as the promoter region.  Promoter regions of actively transcribed genes are 
characterized by evidence of increased Pol II binding, lower levels of DNA 
methylation(Suzuki & Bird, 2008), increased accessibility of DNA(depleted of 
nucleosomes)(Thurman et al., 2012) and many post-translational modifications of 
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histones—H3K4me3 (tri-methylation of lysine-4 on the H3 histone), H3K9ac 
(acetylation of lysine-9 on H3) and H3K27ac(acetylation of lysine-27), to name a 
few(Heintzman et al., 2009).  
Transcriptional regulation can also be effected by enhancers—large stretches of 
DNA that bind multiple TFs and regulate target genes by establishing long-range 
enhancer-gene interactions by forming protein complexes. Enhancers can be 
distal to the gene that they are targeting, in any orientation, upstream or 
downstream of the target gene. Enhancers are also associated with increased 
accessibility to DNA(depleted nucleosome levels)(Thurman et al., 2012), high 
levels of the histone modifications H3K27ac and H3K4me1 and low levels of 
H3K4me3(Heintzman et al., 2009; Tessarz & Kouzarides, 2014). Low levels of 
transcription have also been observed on enhancers, which may have an indirect 
effect on the transcription of target genes(Djebali et al., 2012; T.-K. Kim et al., 2010).  
In my projects the area of transcriptional regulation, I unpacked this complex 
machinery to study each process in detail. I first studied the arrangement of 
nucleosomes around TF binding sites in TSS-proximal and TSS-distal regions. I 
also analyzed the differences in this pattern across binding sites of different TFs, 
wherein some TFs were capable of positioning flanking nucleosomes in a 
periodical manner, whereas others produced a more “fuzzy” arrangement. In 
addition, I observed that although nucleosome formation is correlated with GC 
content of the underlying DNA, binding of TFs overrides this natural preference 
and instead produces a negative correlation between nucleosome enrichment 
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and GC content. I then progressed from the analysis of single TF binding events 
to concurrent binding of multiple distinct TFs in TSS-distal regions. In this project, 
I observed that the binding of multiple TFs is associated with enhancer histone 
modifications that are known to activate transcription of target genes. Multiple-
TF-binding events were also accompanied by high DNA accessibility and 
nucleosome depletion. In a subsequent project, I performed an in-depth study of 
mammalian enhancers and used various histone modification, TF binding and 
sequence data to predict transcriptional enhancers in 11.5 day-old mouse 
embryos in a tissue-specific manner.  
Evolution of Hepatitis C Virus 
Hepatitis C is an affliction of the liver that infects hundreds of millions of people 
worldwide, a majority of whom go on to develop cirrhosis of the liver or 
hepatocellular carcinoma(Averhoff, Glass, & Holtzman, 2012). The infection is 
caused by the Hepatitis C Virus (HCV). HCV is a positive, single-stranded RNA 
virus with a single open reading frame of 9600 nucleotides(KATO, 2000). It 
replicates at a high rate and contains an error-prone RNA polymerase, which 
gives rise to a quasispecies population of the virus in any given sample—
distributions of highly similar but non-identical genomes with a master sequence 
that has the highest replication rate(Lindenbach & Rice, 2005; Simmonds, 2004). 
Due to the high variability of the virus, development of an effective vaccine has 
been a challenge(Simmonds, 2004).  
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In collaboration with MassBiologics Inc., we analyzed evolution of E1 and E2 
coat proteins of HCV in liver-transplant patients from a clinical trial, in response 
to pressure from a novel antibody called MBL-HCV1. This monoclonal antibody is 
targeted towards a highly conserved epitope region on the E2 protein—positions 
412-423. 
The results of the clinical trial established that viral loads of patients who were 
administered MBL-HCV1 returned to pre-liver-transplant levels at a much later 
time point as compared to patients who were treated with placebo. Using a 
systematic method, we compared E1 and E2 sequences across various time 
points in both sets of patients. We identified many positions on E1 and E2 
regions that significantly changed between pre-transplant and post-rebound time 
points. Among these, the most prominent changes were exhibited by two 
positions on the antibody-targeted epitope—N415K/D and N417S. Although 
these two mutations were observed in all antibody-administered patients and 
none of the placebo-treated patients, they did not co-occur on the same viral 
genome. We stipulate that either of these mutations is sufficient for viral escape 
from antibody recognition. In instances where N417S mutation occurred with the 
retaining of the wild type variant at position 415, we propose that N-linked 
glycosylation of position 415 as yet another escape mechanism of the virus from 
antibody recognition. 
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Introduction to various sequencing methods 
 
Since the genomic sequence is the starting point in deciding the fate of the cell, 
the ability to know this sequence has been critical to understanding the 
functioning of the cell. At the same time, its length and structural complexity 
presented challenges in knowing its composition. The first successful attempt to 
“read” nucleotide sequence DNA in its naturally occurring order (henceforth 
referred to sequencing) was by Frederic Sanger in 1977(Sanger & Coulson, 
1975). This method, called “Sanger sequencing”, incorporated chain-terminating 
dideoxynucleotides by DNA polymerase during in vitro DNA replication, and was 
widely used for many years after its inception. In spite of being succeeded by 
more efficient techniques in the last two decades, it is still used in smaller scale 
analysis, owing to its simplicity and reduced error rates. 
Sequencing techniques have seen significant improvements over the last few 
decades, in terms of efficiency, cost and scalability. The most recent sequencing 
methodology is “high-throughput” sequencing, wherein the genomes of many 
clones of the cells of interest are fragmented in a random manner and their ends 
are sequenced. In the case of de novo  assembly, these end-of-fragment 
sequences, called “reads” are then assembled, based on their overlaps, to form 
the original order of nucleotides in the organism. In reference-based assembly, 
the reads are matched against representative combination-genome for the 
species, called a “reference genome”. The various aspects of transcriptional 
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regulation and the possible methods to measure them are illustrated in Figures 1 
and 2. 
 
Figure 1. Illustration of many factors influencing transcription and corresponding 
methods to quantify them. www.encodeproject.org Image credits: Darryl Leja 
(NHGRI), Ian Dunham (EBI), Michael Pazin (NHGRI) 
ChIP-seq  
Adapted from (Landt et al., 2012) 
 
The goals of a genome-wide ChIP(Chromatin ImmunoPrecipitation) experiment 
are to map the binding sites of a target protein with maximal signal-to-noise ratio 
and completeness across the genome. Cells or tissues are treated formaldehyde, 
to cross-link proteins covalently to DNA. This is followed by cell disruption and 
sonication, or in some cases, enzymatic digestion, to shear the chromatin to a 
target size of 100–300 bp(Iyer et al., 2001; Ren, 2000). The protein of interest 
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(transcription factor, modified histone, RNA polymerase, etc.) with its bound DNA 
is then enriched relative to the starting chromatin by purification with an antibody 
specific for the factor. After immuno-enrichment, cross-links are reversed, and 
the enriched DNA is purified and prepared for analysis. Lastly, the DNA is 
analyzed by high-throughput DNA sequencing. 
 
MNase-seq 
MNase-seq (Micrococcal Nuclease-sequencing) is a method to identify DNA 
wound around histones in nucleosomes(Cui & Zhao, 2011). Native chromatin is 
digested by the enzyme microccocal nuclease (MNase), which is then 
followed by the isolation of mononucleosomes, the DNA around which is 
sequenced directly.  
DNase-seq 
This is a method that identifies putative regulatory regions based on their 
hypersensitivity to cleavage the enzyme DNase I. Sequencing genomic 
fragments that are susceptible to DNase cleavage generates genome-wide maps 
of chromatin accessibility, which can be then assessed for functionality. 
(Crawford, 2005; Meyer & Liu, 2014) 
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Figure 2: (Adapted from Terrence S. Furey, Nature Reviews Genetics 13, 840-
852 (December 2012). Comparison of experimental protocols. Experiments to 
detect different aspects of DNA-binding proteins share many of the same steps; 
simplified schematics of the main steps are shown. a) Chromatin 
immunoprecipitation followed by sequencing (ChIP–seq) for DNA-binding 
proteins such as transcription factors. Recent variations on the standard protocol 
include using endonuclease digestion instead of sonication (ChIP–exo) to 
increase the resolution of binding-site detection and to eliminate contaminating 
DNA, and DNA amplification after ChIP for samples with limited cells. b) ChIP–
seq for histone modifications uses micrococcal nuclease (MNase) digestion to 
fragment DNA and can also now be run on low-quantity samples when combined 
with the additional post-ChIP amplification. c) DNase–seq relies on digestion by 
the DNaseI nuclease to identify regions of nucleosome-depleted open chromatin 
where there are binding sites for all types of factors, but it cannot identify what 
specific factors are bound. 
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2. CHROMATIN STRUCTURE AROUND 119 TRANSCRIPTION FACTORS1 
Background 
Eukaryotic DNA is compressed and packaged into a chromatin complex within 
the nucleus. The basic unit of this complex is the nucleosome. A single 
nucleosomal core particle comprises of 146 base pairs of DNA wrapped in 1.6 
turns around a histone octamer(Kornberg, 1974) . The histone octamer is made of 
two copies of four histone proteins - H2A, H2B, H3 and H4. 
 
                                            
1 Jie Wang*, Jiali Zhuang*, Sowmya Iyer*, XinYing Lin*, Troy W. Whitfield, 
Melissa C. Greven, Brian G. Pierce, Xianjun Dong, Anshul Kundaje, Yong 
Cheng, Oliver J. Rando, Ewan Birney, Richard M. Myers, William S. Noble, 
Michael Snyder, Zhiping Weng. 
Sequence features and chromatin structure around the genomic regions bound 
by 119 human transcription factors. 
Genome Res 2012, 22:1798–1812 doi: 10.1101/gr.139105.112 
The ENCODE Project Consortium An integrated encyclopedia of DNA elements 
in the human genome. 
Nature 489, 57–74 (06 September 2012) doi:10.1038/nature11247 
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Figure 3. X-ray structure of the nucleosome core particle (Adapted from 
Reynolds SM et al. PLoS Comput Biol 6(7): e1000834.) At 1.9 Å resolution, the 
two strands of the double-helix in purple and green, with the protein core in grey. 
(A) shows the curvature of DNA around the histone core, with the dyad at the 
top, center. (B) and (C) show 90 degree rotations of the same particle. 
  
Adjacent nucleosomes are separated by “linker DNA”, whose size varies 
between 10 and 80 bp and depends on species and tissue type(Felsenfeld & 
Groudine, 2003). 
Nucleosome positioning across the genome is not random. The most 
distinguishing feature of nucleosomal positioning is the contrast in its enrichment 
and arrangement between regulatory regions and non-regulatory regions. For 
instance, promoter regions (stretches of DNA surrounding Transcription Start 
Sites on either side) are characteristically depleted of nucleosomes. In contrast, 
DNA sequences upstream of the promoter typically contain well-positioned 
nucleosomes. Another interesting observation is that the phasing of the 
nucleosome is well-defined in DNA that is closer to the TSSs(named +1/-1, +2/-2 
and so on) and gets more fuzzy in DNA that is farther away. As seen in Figure 4, 
this conformation is conserved across eukaryotic species to a large extent. 
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Figure 4.  Adapted from Bai et al Volume 26, Issue 11, November 2010, Pages 
476–483 Schematic representation of typical in vivo nucleosome positions in S. 
cerevisiae (interpreted from nucleosomal data in several species). Arrow: TSS. 
Yellow oval: nucleosome. The more yellowish the nucleosome, the better it is 
positioned relative to the TSS. The gray ovals overlapping with each other 
represent nucleosomes without any phasing  
 
The advent of high-throughput genomic techniques allowed systematic mapping 
of nucleosomes, and more recent studies showed that most genomic DNA is 
nucleosomal and that functional TF binding sites tend to be located in 
nucleosome-depleted regions(Guertin & Lis, 2010; John et al., 2011) . Nonetheless, 
some TFs are capable of remodeling nucleosomes in the absence of additional 
factors, and other TFs can recruit nucleosome remodelers to reposition or evict 
nucleosomes and expose TF binding sites(Berger, 2007; Clapier & Cairns, 2009). 
Furthermore, it was reported that TF binding sites are flanked by multiple well-
positioned nucleosomes(Fu, Sinha, Peterson, & Weng, 2008; Valouev et al., 2011). 
The precise positioning of nucleosomes plays an important role in DNA 
accessibility and is one of the deciding factors in transcriptional regulation and 
therefore gene expression. Prior observations about nucleosome positioning 
primarily examined DNA sequences in TSS-proximal regions. Our study 
examined properties of genome-wide nucleosome enrichment and arrangement 
around Transcription Factor binding sites both proximal and distal to TSSs.  First, 
we find that TFs prefer to bind DNA that is GC-rich and nucleosome-depleted. 
These TF binding sites are flanked by well-positioned nucleosomes, and many of 
these features show cell type specificity.  We also observed that TF binding 
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events override the innate sequence rules of nucleosome occupancy and 
possibly regulate the arrangement of flanking nucleosomes. The GC-richness 
could be contributing to the regulation of TF-binding because in the absence of 
TF binding in vivo, we observe nucleosome enrichment in the same regions.  
 
Results 
Nucleosome positioning around ChIP-seq peaks  
It is well known that transcription has a profound impact on nucleosome 
occupancy: Active TSSs in all eukaryotes are flanked by an upstream 
nucleosome-depleted region and several well-positioned downstream 
nucleosomes(Radman-Livaja & Rando, 2010). We previously reported that the 
binding sites of the insulator binding protein CTCF were flanked by an array of 
strongly positioned nucleosomes, shown as a periodic oscillatory pattern in the 
average nucleosome occupancy profile centered on CTCF binding site(Fu et al., 
2008). Another study showed that NRSF (also called REST) binding sites are 
flanked by positioned nucleosomes in CD4+ T cells, CD8+ T cells, and 
granulocytes(Valouev et al., 2011). In order to investigate where TF binding peaks 
were located with respect to nucleosomes, we computed an average 
nucleosome occupancy profile centered on the peak summits of each TF with 
available ChIP-seq data in GM12878 or K562 cells (Figure. 5A,B for YY1 in 
GM12878 cells). We had ChIP-seq data for 51 TFs in GM12878 cells, 73 TFs in 
K562 cells, and 32 TFs in both cell lines. Some TFs were tested by multiple labs 
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in the same cell line, and we included all these data sets. To account for the 
impact of transcription, we computed the average nucleosome profile anchored 
on TSS-proximal and TSS-distal peak summits separately. Nucleosome profiles 
anchored on TSS-proximal peaks were oriented such that the nearest transcript 
is downstream from the anchor. We further stratified peaks in each data set as 
top, middle, and bottom thirds according to the ChIP-seq signal, reflecting the 
extent to which a peak is bound by the TF (averaged over a population of cells). 
We distinguish nucleosome occupancy and nucleosome positioning, with 
occupancy defined as the area under the occupancy profile and positioning 
defined as the regularity of the oscillatory pattern in the occupancy profile. Thus, 
the regions around TSS-proximal summits tend to show lower nucleosome 
occupancy and lower nucleosome positioning than regions around TSS-distal 
summits (Figure. 5A,B). This difference may reflect the effects of RNA 
polymerase on chromatin structure(Weiner, Hughes, Yassour, Rando, & Friedman, 
2010). Within the proximal and distal categories, the top, middle, and bottom third 
peaks, which correspond to the peaks with strongest, medium, and weakest TF 
binding, tended to show the greatest, medium, and weakest nucleosome 
positioning (Figure. 5A,B). Thus regions that are more strongly bound by TFs are 
flanked by better-positioned nucleosomes. 
The cohesin components SMC3 and RAD21 show the most striking patterns of 
positioned flanking nucleosomes, similar to what we previously reported for 
CTCF(Fu et al., 2008) to which these factors bind(Parelho et al., 2008). Two other 
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TFs—CTCFL (a paralog of CTCF) and ZNF143 (a zinc-finger protein with a long 
motif)—also show striking patterns of positioned flanking nucleosomes. The 
binding sites for ∼70% of the tested TFs are flanked by positioned nucleosomes, 
indicating that this is a general phenomenon for most TFs. To quantify the 
regularity of nucleosome positioning around TF binding sites, we applied Fourier 
transforms to the nucleosome occupancy profiles, yielding power spectra. The 
height of the power spectrum at the spatial frequency corresponding to the 
nucleosomal repeat length was used as an indicator of how periodically 
nucleosomes were positioned. The spectrum height correlated significantly with 
the extent of positioning of the –1 and +1 nucleosomes (measured as the 
maximum of the nucleosome occupancy profile). Thus, how well the –1 and +1 
nucleosomes are positioned strongly predicts how periodically the flanking 
nucleosomes are positioned. 
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Figure 5. Chromatin structure and GC content around TF binding regions. (A,B) 
Nucleosome occupancy profiles anchored on the summits of TSS- proximal (A) 
and TSS-distal (B) peaks of YY1 grouped by ChIP-seq signal strength: top 
(green), middle (red), and bottom (blue) third peaks in terms of ChIP-seq signal. 
Nucleosome depletion for the top third peaks is shown as D in each panel. (C ) 
Distribution of nucleosome depletion ‘‘D’’ across all tested TFs, with peaks 
stratified according to TSS proximity (proximal or distal) and ChIP-seq signal 
strength (top, middle, or bottom third). P-values for pairwise comparisons based 
on paired Wilcoxon rank-sum tests are: P1 = 8.2 x 10-17, P2 = 7.6 x 10-21, P3 = 
3.8 x 10-23, P4 = 8.8 x 10-10, P5 = 1.1 x 10-9, P6 = 1.1 x 10-11, and P7 = 6.6 x 
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10-22. (D) TF binding is correlated with significantly more nucleosome depletion 
than TSS. Wilcoxon rank-sum test P-values are shown separately for GM12878 
and K562 cells. For the box plots in C and D, only those subcategories with 200 
or more peaks are included, and whiskers represent the 1.5 inter-quartile range. 
(E) Nucleosome occupancy genome-wide is correlated with GC%. The smoothed 
density scatter plot contains 40,000 data points; each data point is a randomly 
chosen 250-bp region of the human genome. (Black dots) Those regions that 
overlap with ChIP-seq peaks. (Black line) Least square fit. Pearson correlation 
coefficient = 0.62; P-value < 2.2 x 10-16. (F ) Comparison of in vivo (green) and 
in vitro (black) nucleosome occupancy profiles around peak summits of YY1. 
GC% profile around the same summits is plotted in orange. Note elevated GC% 
at summit coincides with high in vitro nucleosome occupancy and low in vivo 
nucleosome occupancy.  
  
Most TFs bind at GC-rich, nucleosome-depleted, and DNase I-accessible 
regions 
The nucleosome occupancy profile dips at the peak summits of most TFs 
(Figure.  5 A,B) indicating that TFs prefer to bind nucleosome-depleted regions or 
that the binding of a TF excludes nucleosomes. In the vicinity of TSS-proximal 
summits, lower nucleosome occupancy is seen in the direction of transcription 
than upstream of transcription. We define nucleosome depletion as the amount 
that nucleosome occupancy dips at the peak summit, as compared to the 
nucleosome occupancy at 2 kb from the summit (considered as background). 
TSS-proximal summits show significantly greater nucleosome depletion than 
TSS-distal summits (Figure. 5C). It is well known that the binding of the 
transcriptional machinery to the TSS excludes nucleosomes to a considerable 
extent(Radman-Livaja & Rando, 2010). Indeed, average nucleosome occupancy 
anchored on the TSS shows an overall loss of nucleosomes. Interestingly, we 
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observed that TSS-proximal TF peak summits show a significantly greater 
depletion in nucleosome occupancy than do TSSs (Figure. 5D). The median 
nucleosome depletion at the summits of TSS-proximal peaks is 0.56 for 
GM12878 cells and 0.59 for K562 cells, significantly greater than the maximal 
nucleosome depletion around TSS (0.42 for GM12878 cells and 0.48 for K562 
cells; Wilcoxon rank-sum test P-value = 7.1 × 10−28 and 1.1 × 10−22, 
respectively). Within the proximal and distal categories, the top, middle, and 
bottom third peaks showed greatest, medium, and weakest nucleosome 
depletion, respectively (Figure. 5C). This result indicates that TFs and 
nucleosomes compete for the genomic DNA and that stronger TF binding is 
correlated with greater nucleosome depletion, above and beyond the effect of 
transcription. 
The peaks of seven TFs (BRF2, HDAC8, TRIM28, SETDB1, WRNIP1, ZNF274, 
and ZZZ3) do not show nucleosome depletion, nor are these peaks flanked by 
well-positioned nucleosomes, indicating these TFs tend to bind nucleosomal 
DNA. Three of these TFs function with each other to repress transcription. 
SETDB1 is a histone methyltransferase that catalyzes H3K9me3, which signals 
for the silencing of euchromatic genes(Bilodeau, Kagey, Frampton, Rahl, & Young, 
2009). TRIM28 (commonly known as KAP1) represses transcription by recruiting 
SETDB1(C. Wang, Rauscher, Cress, & Chen, 2007). ZNF274 is a zinc-finger 
containing TF that binds to the 3′ end of zinc-finger coding genes and recruits 
chromatin-modifying proteins such as SETDB1 and TRIM28, which leads to 
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transcriptional repression(Frietze, O'Geen, Blahnik, Jin, & Farnham, 2010). HDAC8 is 
a histone deacetylase and a transcriptional repressor. We caution that the 
HDAC8 ChIP-seq data set had only 287 peaks. BRF2 is a component of the RNA 
Pol III machinery(Moqtaderi et al., 2010). WRNIP1(commonly known as WHIP) 
regulates DNA synthesis. ZZZ3 is a component of the ATAC complex and a 
histone H3 acetyltransferase and has been shown to acetylate both free and 
nucleosomal H3(Y. L. Wang, Faiola, Xu, Pan, & Martinez, 2008). 
We next asked whether the intrinsic DNA sequence properties of ChIP-seq 
peaks contribute to nucleosome depletion. In an earlier study, we reported a 
strong correlation between GC-rich sequences and their potential to form 
nucleosomes(Peckham et al., 2007). In vitro data also indicate that GC-rich 
sequences promote nucleosome formation(Valouev et al., 2011). Indeed, there is 
positive correlation between nucleosome occupancy and GC content for 
randomly chosen 250-bp regions of the genome (r = 0.62 and P-value < 2.2 × 
10−16) (Figure. 5E) Many of those regions that overlap ChIP-seq peaks (Figure. 
5E black dots) are located above and to the left of the best-fit line, indicating that 
they have high GC% and low nucleosome occupancy. Compared with the 
average GC content of 40% in the human genome, ChIP-seq peaks are 
considerably more GC rich (61 ± 5% for TSS-proximal peaks and 53 ± 6% for 
TSS-distal peaks across the TFs). The high GC content may be due to the GC-
richness of some TF motifs, but the motif sites are much smaller than peaks (8–
21 bp vs. ∼250 bp), and we found similar GC patterns around TF summits 
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without a motif site (data not shown). We conclude that TFs tend to bind GC-rich 
regions in the genome, regardless of the distance from the TSS. These results 
are seemingly contradictory—GC content is highly predictive of sequences that 
promote nucleosome formation, yet the GC-rich sequences surrounding TF 
binding sites are nucleosome-depleted in vivo. 
To determine whether TF binding sites are, indeed, favorable sites for 
nucleosome formation, we used recent data from in vitro reconstitution of human 
genomic DNA into nucleosomes(Valouev et al., 2011) to construct in vitro 
nucleosome occupancy profiles around ChIP-seq peaks, confirming that in vitro 
nucleosome occupancy is much higher on the peak compared with flanking 
regions for the vast majority of TFs ((Figure. 5F for YY1). Thus, TFs or their 
cofactors (such as chromatin remodelers) prevent the formation of nucleosomes 
or evict nucleosomes at these GC-rich locations of the genome. 
Chromatin structure around cell-line–specific TF binding regions 
In order to further investigate the relationship between TF binding and chromatin 
structure, we examined two sets of cell-line–specific ChIP-seq peaks for each 
TF—the set of peaks detected in GM12878 but not in K562 and the set of peaks 
detected in K562 but not in GM12878. We computed nucleosome occupancy 
profiles and DNase I cleavage profiles anchored on the summits of these two 
sets of peaks separately in each cell line (Figure. 6 A,B for YY1). Strikingly, the 
peaks that were occupied by a TF in GM12878 (or K562) but not occupied by the 
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TF in K562 (or GM12878) tend to be occupied by a nucleosome in K562 (or 
GM12878), similar to the in vitro nucleosome profiles of these peaks. 
Accordingly, the increase in nucleosome occupancy is reflected in decreased 
DNase I cleavage in K562 (or GM12878). For many TFs, the ChIP-seq peaks 
that were occupied by a TF in GM12878 (or K562) but not occupied by the TF in 
K562 (or GM12878) were no longer flanked by positioned nucleosomes in K562 
(or GM12878), yet positioned nucleosomes were observed for other TFs, albeit 
at a lesser extent of positioning than the nucleosomes flanking TF-occupied 
peaks. Thus, for the same set of genomic sequences in two cell lines, TF binding 
level deviates from thermodynamic preference for nucleosome formation—TF 
binding either was enabled by, or caused, cell-type–specific depletion of 
nucleosomes from intrinsically favorable genomic locations. 
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Figure 6: Chromatin structure around YY1 ChIP-seq peaks occupied differentially 
between GM12878 and K562. (A) Nucleosome occupancy profiles (solid lines) 
and DNase I cleavage profiles (dashed lines) anchored on the summits of YY1 
peaks in GM12878 but not in K562. Note the average nu- cleosome occupancy 
at these peaks (x = 0) is lower in GM12878 than in K562, while the average 
DNase I cleavage at these peaks is higher in GM12878 than in K562. (B) Same 
as A, but around the summits of YY1 peaks in K562 but not in GM12878. (C ) 
Nucleosome occupancy profiles in K562 anchored on the summits of the ChIP-
seq peaks occupied by YY1 in GM12878 but not in K562. These 11,079 peaks 
were divided into two groups: 6754 peaks were bound by one or more TFs in 
K562 (dashed line), and 4325 peaks were not bound by any TF for which we had 
ChIP-seq data in K562 (solid line). Note high nucleosome occupancy at the 
summits of the unoccupied peaks (x = 0) and the lack of positioned nucleosomes 
flanking the unbound peaks, in sharp contrast to the lack of nucleosome 
occupancy at the peak summits and well-positioned nucleosomes flanking the 
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peaks bound by other TFs. (D) Same as C, but around the summits of the ChIP-
seq peaks occupied by YY1 in K562 but not in GM12878. 
We further partitioned the peaks occupied by a TF in GM12878 (or K562) but not 
occupied by the TF in K562 (or GM12878) into two subsets: group 1 peaks that 
overlapped with one or more ChIP-seq peaks of any other TF tested in K562 (or 
GM12878), and group 2 peaks that did not overlap any ChIP-seq peaks in K562 
(or GM12878). For the vast majority of the TFs, nucleosome occupancy profiles 
for the group 2 peaks show high nucleosome occupancy on the peak and no 
positioned nucleosomes flanking the peak. In contrast, the group 1 peaks show 
nucleosome depletion on the peak and well-positioned nucleosomes flanking the 
peak (Figure. 6C,D). The ChIP-seq data we have only cover up to 10% of TFs in 
a particular cell line, thus group 2 peaks can still be bound by other TFs for which 
we had no data, which could account for any residual pattern of nucleosome 
positioning. These results further strengthen the correlation between TF-binding 
and flanking positioned nucleosomes and indicate that such correlation can be 
regulated in a cell-type–specific manner. 
Discussion 
We integrated ChIP-seq data with nucleosome positioning and DNase I cleavage 
data in two cell lines (GM12878 and K562) to study the interplay between TF 
binding and chromatin structure. We found that the ChIP-seq peaks of most TFs 
correspond to GC-rich, nucleosome-depleted, and DNase I-accessible regions, 
flanked by well-positioned nucleosomes. We may have underestimated the 
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number of TFs whose binding regions are flanked by positioned nucleosomes, 
because we simply averaged over all peaks in each ChIP-seq data set. If subsets 
of peaks are flanked by well-positioned nucleosomes, and the positions of the 
nucleosomes are offset from each other between the subsets, then averaging 
may mask the signal. Another ENCODE companion paper clusters peaks by the 
flanking nucleosome occupancy patterns and reports that subsets of peaks are 
flanked by positioned nucleosomes for almost every TF(Kundaje et al., 2012). That 
paper also investigated the positional patterns of nucleosomes with modified 
histones. 
We further investigated the regions that were bound by a TF in GM12878 but not 
in K562 and vice versa and found that these regions are typically occupied by a 
nucleosome in the cell line that the TF does not bind, and the increase in 
nucleosome occupancy is perfectly correlated with a decrease in DNase I 
cleavage. Consistent with previous findings that GC-rich sequences tend to form 
nucleosomes(Peckham et al., 2007), we found that TF binding regions show locally 
elevated in vitro nucleosome occupancy compared to flanking regions, indicating 
that these regions are intrinsically nucleosomal unless they are bound by TFs. 
Indeed, He et al. found that androgen treatment dismissed a central nucleosome, 
which was flanked by a pair of marked nucleosomes, to reveal androgen receptor 
binding sites(He et al., 2010). Taken together, our results show that a strong 
correlation between TF binding and positioning of nearby nucleosomes is likely a 
universal phenomenon for all TFs. The binding of a single TF is unlikely to 
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position flanking nucleosomes (a single TF is thought to have lower affinity for 
DNA than a nucleosome)(Felsenfeld, 1996), but multiple TFs tend to bind to 
neighboring regions, and they collectively may be able to position nucleosomes. 
Alternatively, chromatin remodelers may have configured the chromatin 
structures around TF binding regions in a cell-type–specific fashion to facilitate 
TF binding. It is also possible that TFs and chromatin remodelers work together 
to establish the chromatin structure. 
Recent work compared chromatin accessibility before and after induction of the 
Drosophila heat shock transcription factor (HSTF)(Guertin & Lis, 2010)  and the 
mammalian glucocorticoid receptor (GR)(John et al., 2011); these studies 
concluded that the chromatin was already accessible prior to induction. Our 
results go beyond these studies by showing that positioned nucleosomes 
constitute the chromatin structure around the binding regions of most TFs. We 
suggest that the GC-richness of TF binding regions may be a mechanism for 
preventing unintended TF-binding, in that a nucleosome would tend to occupy 
the region until it is evicted, possibly by chromatin remodelers or by multiple TFs 
in concert. 
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3. ANALYSIS OF MULTIPLE TRANSCRIPTION FACTOR OCCUPANCY IN 
THE HUMAN GENOME 
 
Introduction 
Regulation of gene expression programs is essential for both normal 
development and formulating appropriate responses to environmental stimuli, 
and conversely, dysregulation of expression programs can lead to disease. 
Deciphering these programs, however, is challenging because transcriptional 
regulation depends on complex mechanisms that vary by cell type, by gene and 
by environmental condition. In this work, we investigate one type of gene 
regulatory mechanism, wherein multiple transcription factors (TFs) bind to a 
single genomic region to co-regulate one or more target genes.  
Initial descriptions of this phenomenon were confined to single loci.  For example, 
the most extensively studied example of coregulation by multiple TFs is the IFNβ 
enhanceosome, which is composed of eight TFs that cooperatively bind to a 55-
bp enhancer to ensure rapid induction of IFNβ upon viral infection(Panne, 2008; 
Thanos & Maniatis, 1995). Since then, several studies have investigated 
mechanisms of TF cooperativity (reviewed in (Spitz & Furlong, 2012)). Siggers et 
al. demonstrated the influence of the non-DNA-binding cofactors Met4 and Met 
28 on the sequence specificity of the Met4-Met28-Cbf1 complex in S. 
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cerevisiae(Siggers, Duyzend, Reddy, Khan, & Bulyk, 2011). Other studies 
proposed indirect mechanisms such as binding to common cofactor(Merika, 
Williams, Chen, Collins, & Thanos, 1998), opening chromatin by pioneering 
factors(Biddie et al., 2011), and preventing nucleosome formation by a 
placeholder TF(Voss et al., 2011).  
More recently, the extensive application of chromatin immunoprecipitation of TFs 
followed by deep sequencing (ChIP-seq)(Johnson, Mortazavi, Myers, & Wold, 2007; 
Robertson et al., 2007)has greatly facilitated the genome-wide identification of 
regions bound by multiple TFs. Mooman et al. reported an abundance of 
genomic regions that were bound by seven Drosophila TFs(Moorman et al., 2006). 
The ENCODE and modENCODE consortia have generated ChIP-seq datasets 
for hundreds of human, mouse, fly and worm TFs in multiple cell types.  Two 
modENCODE studies performed genome-wide analyses on regions bound by 
multiple TFs, which they called High Occupancy Targets or HOT regions(Gerstein 
et al., 2010; modENCODE Consortium et al., 2010) The ENCODE consortium also 
defined human HOT regions with a large collection of ChIP-seq datasets and 
studied co-association between TFs(Consortium, 2012). 
Although these studies have identified many examples of co-regulation by 
multiple TFs, multiple genome-wide analyses of HOT regions have suggested 
that TFs often bind to these regions non-specifically and perhaps non-
functionally. The C. elegans modENCODE study stratified HOT regions by TF 
complexity, i.e., the number of TFs bound to a HOT region. Surprisingly, low 
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complexity regions (1-4 TFs) were more enriched in TF sequence motifs than 
high complexity regions (>15 TFs). Meanwhile, the genes near low complexity 
regions were also significantly more enriched for tissue-specific expression. The 
authors thus concluded that many TFs bound to HOT regions non-
specifically(Gerstein et al., 2010).  The Drosophila modENCODE study identified 
correlations between TF complexity and levels of epigenetic features such as 
nucleosome density, histone variants, and histone modifications(modENCODE 
Consortium et al., 2010). The authors found that, for all the TFs that showed a 
preference in motif enrichment across varying TF complexity levels, the 
enrichment was for low complexity regions, suggesting that these TFs bound 
nonspecifically to the HOT regions. A later study tested 108 of the fly HOT 
regions defined by the modENCODE consortium using transgenic embryos and 
found that 94% of them functioned as transcriptional enhancers compared with 
39% of control regions(Kvon, Stampfel, Yáñez-Cuna, Dickson, & Stark, 2012)This 
study also reported that the spatial activity patterns of HOT regions did not 
overlap extensively with the expression patterns of the bound TFs. Thus, the 
authors proposed that TFs often bind to non-functional regions or bind non-
functionally to functional enhancers(Kvon et al., 2012). Finally, an ENCODE study 
reported that the HOT regions were enriched in DNase I hypersensitivity signal 
and strongly overlapped with TF ChIP-seq peaks that did not contain sequence 
motifs, again suggestive of non-specific binding(Yip et al., 2012).  
Do regions bound by multiple TFs actively regulate gene expression, or are these 
  
29 
regions merely a functionless byproduct of the highly accessible chromatin at 
these regions? Do all TFs participate in non-specific binding at HOT regions, or is 
the phenomenon linked to a subset of TFs? In this study we address these 
questions by analyzing DNA and chromatin features around HOT regions in five 
human ENCODE cell lines—GM12878, K562, H1-hESC, HepG2 and HeLa-S3. 
We focus on HOT regions that are distal to annotated genes (more than 1 kbp 
from the transcription start site) in order to minimize the direct impacts of the 
transcriptional machinery.  Compared with regions of lower TF complexities, the 
HOT regions with higher TF complexities are enriched in many histone 
modifications indicative of active enhancers, show increased binding by RNA Pol 
II suggestive of transcriptional activities, are more sensitive to cleavage by 
DNase I, and show reduced and fuzzier nucleosomal occupancy suggestive of 
dynamic nucleosome exchanges in these regions. Indeed, the vast majority of 
HOT regions with high complexity overlap with genomic segments annotated as 
enhancers. Lastly, we discovered significant enrichment in motifs of lineage-
determining TFs in regions of high complexity as compared to low-complexity 
regions.  
Results 
Genomic regions occupied by multiple TFs  
Using the recently reported ENCODE data, we merged the peaks of all ChIP-seq 
experiments performed in the same cell line to define HOT regions that 
corresponded to regions bound by multiple TFs. Following previous studies {cite 
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modENCODE papers}, the TF complexity of a HOT region is defined as the 
number of TFs whose ChIP-seq peaks compose the region. To test the 
hypothesis that TFs prefer to bind in close proximity to at least one other TF, we 
carried out a simulation in which we generated a set of control HOT regions by 
merging random genomic intervals matched by size to ChIP-seq peaks. The 
results (Figure 7 (a) for K562) show that real TF binding data exhibit significantly 
greater clustering of TF binding than predicted by the simulation (p-value < 2.2 E-
16 for all five cell lines studied, chi-square goodness-of-fit test). 
 
Figure 7: Distribution and conservation of TF complexity in HOT regions (a) 
Histogram of observed and expected frequencies of HOT regions across 
complexities in K562 cells. Green bars represent experimentally observed HOT 
regions formed by merging ChIP-seq peaks of TFs in K562. Purple bars 
represent HOT regions formed by merging random genomic regions of equal size 
to ChIP-seq peaks being compared. Inset shows experimentally observed 
number of regions for TF complexities > 10. (b)  Bars show log10 
(observed/expected frequencies) of categories of base pairs defined by whether 
they are in GM12878 (G and g for high and low complexity sub-categories), K562 
(K and k for high and low complexity sub-categories) and Hep-G2 (H and h  for 
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high and low complexity sub-categories). Highest bar is that of high-complexity 
bases in all 3 cell lines. 
Genomic positions that are of high TF complexity in one cell line are more 
likely to be of high TF complexity in other cell lines 
A recent study combined sequence and chromatin-based features and concluded 
that individual TFs tend to bind in a cell-type specific manner(Arvey, Agius, Noble, 
& Leslie, 2012). To analyze the cell type specificity of HOT regions, we identified 
the TFs for which ChIP-seq experiments were performed in three cell lines 
(GM12878, K562 and HepG2) and derived HOT regions for these 10 TFs in each 
cell line. Next we binned all loci in the human genome by TF complexity: 0, low 
(1-5), and high (6–10). Combining these bins across three cell types, we 
computed the fraction of genomic loci in each of 27 states. If the genomic 
locations a TF binds to in one cell line were independent of the locations the TF 
binds to in another cell line, then the expected probability for each state would be 
the product of the fractions of the bins in the respective cell lines. We then 
computed the enrichment (log ratio) of observed over expected probabilities, 
which is a measure of the consistency of TF complexity across different cell lines. 
Figure 7(b) plots the log10 (fold ratios) of the 27 states in descending order, with 
the states colored according to the number of cell lines with the same complexity 
bin. Our results indicate that the TF complexity of a HOT region is highly 
conserved across cell lines. The state that shows the highest log ratio represents 
loci that have high TF complexity in all three cell lines (GKH), i.e., a position 
bound by more than 5 TFs in one cell line is highly likely to be bound by more 
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than 5 TFs in the other two cell lines as well. For instance, we calculated that the 
probability of a base having high complexity in GM12878 and K562 given that it 
is of high complexity in HepG2 is 2000 times as much as it would be if it were of 
low complexity in HepG2 (Methods).  The sets of states with high log ratios 
(colored in blue or pink in Figure 7(b)) include those with high complexities in two 
cell lines as well as those with low complexities in two or three cell lines.  
 
Chromatin in regions of high complexity is enriched in activating histone 
modifications 
Since TF binding activity has been frequently linked to epigenetic 
modifications(Guccione et al., 2006; Kouzarides, 2007; Lin et al., 2007; Lupien et al., 
2008), we queried for enrichments or depletions in any particular histone 
modifications around HOT regions. Using all available ChIP-seq histone 
modification data in the five cell lines, we computed the average level of each 
histone modification across the 250-bp window around the median of peak 
summits in each HOT region. Similarly, we computed the average histone 
modification level over randomly chosen regions matched in size and number of 
TF peaks with the HOT regions. We then calculated the log10(fold enrichment) of 
observed histone modification level over control for HOT regions with each TF 
complexity (11-25 were added to one bin). Figure 8 plots the distributions of 
histone modification levels for HOT regions that are distal to TSS as a function of 
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TF complexity. H3K4me1, H3K4me2, H3K4me3, H3K27ac, and H3K9ac show 
marked increases (p-value < 2.2E-16 for Wilcoxon rank-sum test between the 
two extreme groups of HOT regions with TF complexities 1-5 and 21-25 
respectively). The increasing patterns for these activating histone marks were 
observed across all five cell lines studied, even though the TF composition of the 
HOT regions varied among the cell lines depending on ChIP-seq data availability. 
In contrast, the repressive histone mark H3K27me3 displayed a significant 
decrease in enrichment(p-value < 2.2E-16).  
H3K4me1 is a well-studied histone modification frequently associated with 
enhancers(Heintzman et al., 2009) We observed significantly higher H3K4me1 in 
regions of higher TF complexity. H3K4me3 is highly enriched in promoter regions 
of actively transcribed genes but has also been detected in significant levels in 
active enhancers(Pekowska et al., 2011) albeit in lower levels compared with 
promoters. We also observed lower levels of H3K4me3 in TSS-distal HOT 
regions compared with TSS-proximal ones (data not shown). Nevertheless, we 
observed increasing enrichment of H3K4me3 for TSS-distal HOT regions with 
greater TF complexity. Histone acetylation has been shown to increase 
chromatin accessibility(Eberharter, 2002; Görisch, Wachsmuth, Tóth, Lichter, & Rippe, 
2005; Lee, Hayes, Pruss, & Wolffe, 1993; Struhl, 1998) via removal of positive 
charges on histone tails and subsequent weakening of histone-DNA interaction. 
H3K9ac and H3K27ac showed the highest magnitude of increase across the 
range of TF complexities. Cooperative binding of transcription factors is a 
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hallmark of cis-regulatory activity at enhancers.  
H2A.Z, a variant of the histone protein H2A, also shows significantly greater 
enrichment for HOT regions with greater TF complexities (p-value < 2.2E-16). 
H2A.Z has been associated with reduced nucleosome stability(Chunyuan Jin, 
2007) and formation of open chromatin states in DNA repair processes(Y. Xu et 
al., 2012). Since HOT regions are also characterized by reduced nucleosome 
occupancy (see below), H2A.Z enrichment in HOT regions may be critical for 
displacement or eviction of histone proteins to make chromatin more accessible 
to DNA. 
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Figure 8. Patterns of chromatin enrichment in HOT regions (a)-(e) Median 
(dark line) and 25-75th percentiles (light shaded region) of enrichments of 
activating histone marks in K562, as a function of TF complexity. Activating 
histone marks are more enriched in higher complexity. (f) Median (black line) and 
25-75th percentiles (grey shaded area) of same measurement for H3K27me3, a 
repressive histone mark. Pattern shows no change in enrichment across 
complexities. 
 
HOT regions with higher TF complexities are more likely to be annotated as 
enhancers and promoters 
Having observed enrichment of individual histone modifications in HOT regions, 
we asked whether HOT regions exhibit enrichment in combinations of histone 
modifications. We used Segway(Hoffman et al., 2012), a dynamic Bayesian 
network method, to identify chromatin states with combinatorial patterns of 
histone modifications (see Methods). We trained Segway on nine histone 
modifications (H3K4me1, H3K4me2, H3K4me3, H3K27ac, H3K27me3, H3K9ac, 
H3K36Me3 and H4K20Me1) for which ChIP-seq data were available in all five 
cell lines we studied. Based on these data, Segway divided the entire genome 
into non-overlapping segments, each of which was labeled with one of 25 states 
such that segments that belonged to the same state showed similar patterns of 
histone modifications. For instance, segments in two states labeled as 
“enhancer” were highly enriched in H3K4me1, H3K4me2 and H3K27ac. Besides 
the canonical enhancer modifications, we also verified the enhancer classification 
by interrogating EP300 binding. The states labeled as “enhancer” by Segway 
displayed increased enrichment for EP300, further confirming the annotation. 
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Two states labeled “promoter” showed high enrichment in H3K4me3 and 
H3K4me2—both hallmarks of promoters. For the purposes of this study, we 
merged the remaining 21 Segway states into a single state called “other”. 
As Figure 9 (a) illustrates, the fractions of HOT regions that overlapped with 
enhancer and promoter segments increased drastically with TF complexity. The 
higher number of bound TFs may indicate a more active state of the HOT region 
and therefore correlate with higher levels of the combinations of histone 
modifications known for transcriptional activation.  
Furthermore, we interrogated binding strengths of EP300 and POLR2A with 
respect to TF complexity. These are non-sequence-specific TFs whose peaks 
were not included to form HOT regions. EP300 is a histone 
acetlyltransferase(Ogryzko, Schiltz, Russanova, Howard, & Nakatani, 1996) that is 
predictive of enhancer regions(Visel et al., 2009). POLR2A is the largest subunit of 
RNA Polymerase II, which is responsible for transcriptional initiation(Maston, 
Landt, Snyder, & Green, 2012) and is therefore a reliable indicator of active 
transcription. We found that both EP300 and POLR2A show increased 
enrichments in regions of high TF complexity (Figure 9 (b) and (c)). This finding 
gave more evidence to the relationship between TF complexity and 
transcriptional activity. 
These analyses corroborate our results in the previous section on individual 
histone marks and further show that segments characterized by combinations of 
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activating histone marks as well as marks indicative of open chromatin are 
enriched in regions with high TF complexity.  
 
Figure 9: Enhancer and promoter annotations of HOT regions (a) Each vertical 
bar represents a complexity (1-25), and each colored segment within the bar 
represents a Segway state. The fraction of bases annotated as 
“enhancer”(purple bars) and “promoter”(red bars) increase with TF complexity. 
(b) Median (black line) and 25-75th percentiles(purple shaded region) of 
enrichment of EP300 with respect to TF complexity. HOT regions with higher TF 
complexities tend to be more enriched in EP300 (c) Median (black line) and 25-
75th percentiles(red shaded region) of enrichment of POLR2A with respect to TF 
complexity. HOT regions with higher TF complexities tend to be more enriched in 
POLR2A. 
 
Nucleosome positioning decreases and DNase hypersensitivity increases 
at higher TF complexity 
In a previous study we analyzed nucleosome occupancy around the binding sites 
of a large number of human TFs, observing arrays of well positioned 
nucleosomes flanking TF binding sites(J. Wang et al., 2012). Here we performed 
the same analysis for HOT regions in two cell lines, K562 and GM12878. We 
divided HOT regions into five bins by TF complexity: 1–5, 6–10, 11–15, 16–20 
and 21–25. We then constructed an average profile of nucleosome occupancy in 
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the ± 2000 bp window around the summits of all TF peaks in the HOT regions in 
each bin (Figure 10). In order to avoid possible bias caused by different numbers 
of HOT regions across the bins, for each cell line we randomly down-sampled the 
total number of  HOT regions in each bin to that of the bin with the lowest sample 
size. 
The statistical positioning model suggests that TFs can position nucleosomes. 
According to this model, TFs that bind to genomic DNA act as “barriers” against 
which two neighboring nucleosomes are positioned(Mavrich et al., 2008) (+1 and –
1 nucleosomes), which in turn position the next two neighboring nucleosomes 
(+2 and –2 nucleosomes) and so on. The nucleosome positioning capability of a 
TF can be estimated using the number of visually discernible “peaks” and 
“troughs” in the average nucleosome occupancy profile surrounding the anchor 
TF binding site. We found earlier that TF binding was positively correlated with 
the positioning of neighboring nucleosomes in a cell line specific manner (J. Wang 
et al., 2012). We therefore expected that HOT regions bound by multiple TFs 
would exhibit even greater nucleosome positioning capabilities. In contrast, we 
observed decreased nucleosome positioning for HOT regions with greater TF 
complexities, indicated by diminished peaks and troughs in the nucleosome 
occupancy profiles (Figure 10a). This conclusion remains after we tested several 
ways of anchoring the nucleosome occupancy profiles: using the summits of all 
ChIP-seq peaks, using just the two outer summits in each HOT region, or using 
the median summit position in each HOT region. 
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TFs typically bind to nucleosome-depleted regions (NDR); indeed, we observe an 
NDR at the center of the nucleosome occupancy profiles in Figure 10a. With 
increasing TF complexity, we observed an increase in both the depth and the 
width of the NDR. Accordingly, these regions show increased accessibility by the 
DNase I endonuclease (Figure 10b). Thus, either the binding of multiple TFs 
leads to greater eviction of nucleosomes, or regions with more open chromatin 
tend to be bound by more TFs.  
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Figure 10: Chromatin structure around HOT regions (a) Aggregate nucleosome 
occupancy profiles in a 2000-bp interval around distal HOT regions anchored on 
ChIP-seq peak summits and grouped by complexity. Highest complexities (21-
25) display least nucleosome positioning. (b) Chromatin accessibility as 
measured by DNase I hypersensitivity in the same intervals as (a). Chromatin 
around highest regions of highest complexities (21-25) are most accessible to 
DNase I cleavage as compared to other complexities. Dashed line represents 
location of peak summits. 
 
Discussion 
Do regions bound by multiple TFs actively regulate gene expression, or are these 
regions merely a functionless byproduct of the highly accessible chromatin at 
these regions? Do all TFs participate in non-specific binding at HOT regions, or is 
the phenomenon linked to a subset of TFs? To answer these two questions, we 
analyzed 200 genome-wide datasets across five human cell lines, including 
ChIP-seq of 64 different TFs, ChIP-seq of 8 types of histone modifications and 
variants, DNase I hypersensitivity, and nucleosome occupancy, in conjunction 
with genomic sequences. Our analysis of HOT regions across TF complexity 
allowed us to conclude that the HOT regions with higher complexities are more 
likely to function as enhancers and actively regulate gene expression and that a 
subset of TFs bind to higher HOT regions with greater sequence specificity, in 
comparison with HOT regions with lower complexities.  
Several lines of evidence support that high-complexity HOT regions are active 
enhancers. They are enriched in histone modifications that are characteristic of 
enhancers (e.g., H3K4me3 and H3K27ac), highly sensitive to DNase I cleavage, 
depleted of nucleosomes, vast majority of them overlap with enhancers 
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annotated by Segway, enriched in EP300 binding, and the genes that are 
nearest to these regions are highly expressed. The enrichment of individual 
chromatin features has been reported for HOT regions in worm, fly, and human. 
(Gerstein et al., 2010; modENCODE Consortium et al., 2010; Yip et al., 
2012)produced cell type-specific annotation based on histone modifications and 
variants using the Segway method, and showed that distal regulatory elements 
bound by multiple transcription factors were characterized by enrichment of 
canonical enhancer marks such as H3K27ac and H3K4me1.  
Among these regions, we observed patterns of increasing enrichments in several 
activating epigenetic features with respect to TF complexity. Regions of higher 
complexity were also enriched in combinations of histone modifications that are 
characteristic of enhancers (e.g., H3K4me1 and H3K27ac), highly sensitive to 
DNase I cleavage, depleted of nucleosomes, and also highly enriched in the 
enhancer annotated by the genomic segmentation tool Segway. We also found 
that TFs canonically labeled as “sequence-specific” exhibited different levels of 
sequence-non-specific binding when co-bound with other factors – some showed 
positive correlations between binding affinity and motif presence, while others 
demonstrated increased binding in spite of reduced motif presence with higher 
complexities.  
Earlier studies have consistently indicated that HOT regions are largely neutral 
and a result of accessible DNA. We argue that while there might be some 
widespread low-affinity neutral binding, HOT regions do tend to serve a 
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regulatory function. Our argument is supported by the enrichments of activating 
histone modifications, dynamic nucleosome arrangements and conservation.  
Although our study was focused on distal loci, we found histone marks 
characteristic of promoters, namely, increased enrichment of H3K4me3 and RNA 
Polymerase II in HOT regions of higher TF complexity.  Multiple studies have 
reported the presence of H3K4me3 and RNA-Polymerase activity in active distal 
enhancers(Djebali et al., 2012). From our Segway analysis, we also observe that 
HOT regions with high TF complexity are likely to be enhancers. This leads us to 
hypothesize that the presence of H3K4me3 and Pol II at distal HOT regions are 
due to (1)transcription of enhancer RNAs (eRNAs) at the enhancers{Natoli:we}, 
(2) transcription of distal target genes whose promoters are looped to the 
enhancers(Panne, 2008; Sanyal, Lajoie, Jain, & Dekker, 2012), or combination of 
(1) and (2). Pekowska et al.(Pekowska et al., 2011) analyzed H3K4me1, 
H3K4me2 and H3K4me3 in enhancers and concluded that increases in 
H3K4me2 and H3K4me3 in distal enhancers were correlated with increased 
expression levels of the associated genes in T cell development(Pekowska et al., 
2011). A recent ENCODE study found that enhancers looping to promoters are 
more likely to express eRNAs than enhancers that do not loop(Djebali et al., 
2012). Consistent with these earlier studies, our results indicate that the large 
number of TFs bound to HOT regions can promote the production of eRNAs 
accompanied by H3K4me3, H3K9ac (another histone modification enriched in 
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promoters) and H3K4me2 (known to be enriched in both TSS-distal and TSS-
proximal cis-regulatory regions).  
Another possibility is that high chromatin accessibility at HOT regions with high 
TF complexity enables binding of Pol II without transcription, consequently 
leading to ectopic H3K4me3 enrichment(Spitz & Furlong, 2012). Considering the 
enrichment of other histone modifications and variants like H3K9ac, H3K4me2 
and H2A.Z, it seems unlikely that these enrichments result from unproductive Pol 
II binding. Rather, it is more likely that the coordinated binding of multiple TFs in 
HOT regions lead to enhanced transcriptions at target genes.  
The phenomenon of nucleosome positioning has been observed at transcription 
start sites as well as in the regions immediately flanking transcription factor 
binding sites(J. Wang et al., 2012). However, the effect of TF complexity on 
nucleosome positioning had not been investigated. To our surprise, we found 
that nucleosomes flanking HOT regions with higher TF complexities were less 
well positioned than the nucleosomes flanking HOT regions with lower TF 
complexities. This can be due to a number of reasons: (1) the heterogeneity of 
TFs in different HOT regions; (2) the varying lengths of HOT regions, with higher 
TF complexity regions being typically longer than lower complexity regions; (3) 
greater diversity among higher TF complexity regions than lower complexity 
regions; and (4) greater dynamic interchanges of nucleosomes (and possibly 
TFs) at higher TF complexity regions. We attempted anchoring the nucleosome 
occupancy profiles using the two ChIP-seq peaks at the ends of each HOT 
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region, in an effort to eliminate the effect of varying length of HOT regions (point 
2 above), but it did not improve nucleosome positioning. Despite great 
sequencing depths (1,845,550,856 confidently mapped reads for K562, and 
1,929,303,627 for GM12878(Kundaje et al., 2012)) in the two MNase-seq 
datasets, they are not deep enough for resolving the positions of individual 
nucleosomes at most genomic loci; thus we are not able to address points 1 and 
3 directly.  
We also observed widening and deepening of the NDR regions and increasing 
DNase I hypersensitivity at HOT regions with greater TF complexity. A previous 
study that examined the role that cooperative binding of TFs plays in 
repositioning nucleosomes in yeast(J. A. Miller & Widom, 2003). Another study 
proposed a model of “assisted loading” whereby the binding of one TF molecule 
increases chromatin accessibility which in turn increases the steady-state binding 
of another TF molecule to the same site(Voss et al., 2011). These and a few 
other mechanisms(Spitz & Furlong, 2012) suggest the cooperative effect of TFs 
on nucleosome depletion. Consistent with these studies, our results also support 
that multiple bound TFs can lead to increased nucleosome eviction or 
displacement. 
We then investigated the motif content of HOT regions, aiming to get more 
mechanistic insights into the formation of these regions. We observed increased 
ChIP-seq signal for most TFs at HOT regions with regarding to greater TF 
complexity. This can be simply due to the greater chromatin accessibility at these 
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regions. Indeed, previous studies on human, fly and worm proposed that HOT 
regions were simply genomic regions with the greatest chromatin accessibility 
and suggested that most TFs bind non-specifically to these regions(Gerstein et 
al., 2010; modENCODE Consortium et al., 2010). But most chromatin modifying 
factors do not have sequence specificity; what causes the increased chromatin 
accessibility? Kvon et al. performed an intriguing study on the Drosophila 
melanogaster HOT regions(Kvon et al., 2012) defined by using modENCODE 
ChIP-seq data produced and found that the vast majority of these HOT regions 
act as active enhancers during embryogenesis. 
An explanation for increased binding in higher complexity regions is neutral 
binding of some TFs as a result of open chromatin, (irrespective of motif 
presence) without any apparent contribution to cis-regulatory activity as 
suggested in a previous study on D.melanogaster development(Kvon et al., 
2012). This might be possible, but seems less likely in the light of accompanying 
enrichments in activating histone modifications and higher conservation with 
higher TF complexity. 
 
Methods 
Derivation of HOT regions 
We pooled together a non-redundant set of 153 TF ChIP-seq experiments across 
five cell lines (GM12878, K562, H1-hESC, HepG2 and HeLa-S3) that included at 
most one experiment for each TF-cell line combination. We only included ChIP-
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seq datasets that were annotated as “good quality” by the ENCODE consortium. 
Furthermore, we included only those TFs that have been annotated as 
“Transcription Factor Sequence Specific” or “TFSS”(Consortium, 2012). For each 
cell line, we merged ChIP-seq peak intervals that were either contiguous or 
intersected by 1 or more base, into non-overlapping genomic regions using 
bedtools(Quinlan & Hall, 2010) .We called each merged interval a HOT region. The 
number of TFs whose peaks compose a HOT region is defined as the TF 
complexity of the region. For generality, we include isolated ChIP-seq peaks as 
HOT regions with TF complexity of one. We then removed TSS-proximal peaks, 
defined as those merged regions that lie within 1000 bp of any transcription start 
site (TSS) annotated by GENCODE (version 19).   
The highest TF complexity in each cell type ranged from 18 (H1-hESC) to 31 
(K562), but this number varied based on the available ChIP-seq data in each cell 
line. This analysis can be easily extended to intervals of higher complexity as 
more data become available. 
Conservation of TF complexity across cell lines 
We binned HOT regions in each cell line into three groups: zero complexity 
(represented as a “*” in Figure 7B in the corresponding cell line), 1-5 or low 
complexity (represented in the lower case g, k, and h for GM12878, K562, and 
HepG2 respectively), and >10 or high complexity (represented as G, K, and H for 
the three cell lines). We then computed the frequencies of genomic bases that 
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fall into the 27 states defined by the complexity bins in the three cell lines. In 
comparison, we computed the expected frequencies for each state by multiplying 
the frequencies of the respective bins in the respective cell lines.  
We calculated conditional probability as follows 
P (G,K / H) = P (G,K,H) / P(H) = 0.313 
P (G,K / h) = P (G,K,h) / P(h) = 0.00015 
Histone modification analysis 
We used the histone modification ChIP-seq datasets from the ENCODE March 
2012 freeze. These have been normalized by read depth and made available as 
raw signal files using custom pipelines(Kundaje et al., 2012). The normalized 
histone modification signal corresponds to the enrichment of the histone 
modification at each base. 
For each HOT region, we first identified the median coordinate of ChIP-seq peak 
summits in that region. For the median coordinate ± 125 bases, we measured 
average histone modification enrichment. We then obtained the same 
measurement from randomly chosen genomic background intervals matched by 
lengths and numbers of peaks. The log fold enrichment of a histone modification 
was calculated for each HOT interval as follows: 
log10 (enrichment in HOT region / average enrichment in matched background 
intervals) 
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Segway analysis  
Segway(Hoffman et al., 2012)  was run for each of five cell lines using the ChIP-
seq data of the following seven histone modifications: H3K4me1, H3K4me2, 
H3K4me3, H3K9ac, H3K27ac, H3K27me3, H3K36me3 and H4K20me1. Segway 
was trained on 1% of the human genome and the resulting model was used to 
segment and label the entire genome. Segway produces a partition of the 
genome into non-overlapping segments, with each segment labeled as one of 25 
states, and each label associated with characteristic patterns of the seven 
histone modifications. Genomic annotations such as “enhancer” and “promoter” 
were then derived from the labels, based on the histone modifications they were 
enriched in. We intersected HOT regions with Segway segments and obtained 
the distribution of Segway states for HOT regions with each TF complexity.  All 
bases in each complexity were classified into “enhancer”, “promoter” or “other” 
based on their Segway state. Then for each complexity, the percentage of bases 
that fell into one of the three classifications above was plotted. 
  
  
49 
 
4. TISSUE-SPECIFIC PREDICTION OF ACTIVE ENHANCERS IN 
TRANSGENIC MICE BY INTEGRATION OF MULTIPLE FEATURES 
Introduction 
Gene expression in eukaryotes is a complex process precisely regulated by 
multiple events that include binding of transcription factors, epigenetic alterations 
to DNA, post-translational modification of associated histones, eviction or 
displacement of nucleosomes — all leading to the recruitment of transcription 
machinery at gene promoters and expression of the appropriate genes. 
Regulatory enhancers are genomic segments that play a leading role in this 
process. Upon activation, multiple transcription factors and co-factors bind DNA 
at enhancer regions and activate one or more target genes via multiple 
mechanisms(Panne, 2008; Zhu et al., 2007). Enhancers have been observed to 
drive expression of genes specific to a tissue and are their timely activation is 
crucial in development. Aberrant enhancer activity has also been implicated in 
cancer(Riggi et al., 2014).  Identifying the locations of enhancers is, therefore, 
critical to understanding the biology of cell-type differentiation as well as the 
pathologies of various diseases. At the same time, locating enhancers is not 
trivial and presents a challenging problem since they are not necessarily present 
near their target genes and sometimes regulate their target genes from 
megabases away.  Individual enhancers have been identified and characterized 
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using structural paradigms(Thanos & Maniatis, 1995). While these techniques put 
forth vivid details and enable the in-depth study of specific enhancers, they are 
not useful in predicting them. Moreover, they do not enable the broad study of 
genetic and epigenetic patterns in enhancer elements, since it is not practical to 
apply these methods genome-wide. Computational predictions of enhancers 
based on canonical features of regulatory elements have made many advances 
in addressing this challenge. Enhancers are associated with many sequence and 
epigenetic features—high evolutionary constraint, binding of the histone 
acetylase P300, highly accessible DNA and specific histone modifications, such 
as H3K27ac and H3K4me1 being the most well-studied. One of the earliest 
attempts to computationally predict putative enhancers used high levels of 
sequence conservation in non-coding regions as an predictive 
property(Pennacchio et al., 2006). Pennachio et al used this feature to identify 167 
putative enhancers, which were tested for activity in transgenic mouse enhancer 
assays. 45% of the tested elements tested positive for enhancer activity across 
various tissues in 11.5 day-old mouse embryos. This approach was further 
refined to use “ultraconservation”(Visel et al., 2008)— perfect human-mouse 
sequence conservation of at least 200-bp-long stretches of DNA — as a feature 
to identify an additional small set of distinct developmental enhancers. These 
approaches broadly predicted DNA elements to be enhancers, but did not take 
into account tissue-specificity of enhancers. 
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As more regulatory data was made available in the form of results from ChIP-seq 
(Chromatin Immunoprecitation followed by high-throughput sequencing) 
experiments(Johnson et al., 2007; Robertson et al., 2007), the quality of enhancer 
prediction became more fine-grained to identify activity in specific developmental 
tissues. Visel et al. (Visel et al., 2009)used the binding of cofactor P300 to predict 
enhancers in forebrain, midbrain and limb tissues of embryonic mice with 
accuracies of 87, 88 and 88% respectively. ChIP-seq of P300 was used in a 
subsequent study to accurately identify heart enhancers(Blow et al., 2010), which 
were weakly conserved as compared to enhancers in other tissues. 
The association of tissue-specific enhancer activity with histone modifications 
H3K27ac and H3K4me1(Heintzman et al., 2009) and depletion of H3K4me3(which 
is known for its promoter association) further clarified enhancer models. Nord et 
al(Nord et al., 2013) used H3K27ac to profile forebrain, heart and liver enhancers 
in various developmental stages and found significant differences in H3K27ac 
activity across tissues as well as time pointsH3K27ac was also found to separate 
active and “poised” enhancer state - the latter state was associated with only 
H3K4me1 presence and an absence of H3K27ac(Gabriel E Zentner, 2011; Rada-
Iglesias et al., 2010).. Thus, histone modifications and P300 binding give important 
clues to the presence of transcriptional enhancers and their assays have become 
standard methodology for identifying enhancers. However, the accuracy of most 
of these methods was capped by the fact that at most one or two of the known 
identifying features were used at a time.  
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Subsequent approaches incorporated combinations of features in supervised and 
unsupervised machine-learning techniques to make more sophisticated 
predictions. Rajagopal et al(Rajagopal et al., 2013) utilized 24 histone modifications 
in a modified Random Forest algorithm (RFECS) to predict enhancers in two 
distinct cell types in human cells. Further prediction methods involved clustering 
of profiles of histone modification, DNase accessibility and TF binding in an 
unsupervised or semi-supervised fashion to identify enhancer segments (among 
other genomic annotations like promoter, insulator and so on) across human 
ENCODE cell lines(Ernst & Kellis, 2012; Hoffman et al., 2012). These approaches 
used multiple features but their accuracies were not directly measured with in 
vivo tests. For instance, the accuracy of RFECS was measured by using 
H3K27ac enrichment as a proxy for enhancer activity.  
A direct and reliable method of testing the validity of enhancer predictions was 
built into the transgenic mouse assay technique developed. In this technique, a 
plasmid construct is built out of a candidate enhancer sequence, a minimal 
Hsp68 promoter and a LacZ reporter gene, which is inserted into mouse eggs. 
The mouse embryos are then harvested at 11.5 days. A segment is defined as 
positive for enhancer activity if reproducible LacZ expression is observed in at 
least three independent mouse embryos, else it is defined as negative. The 
VISTA Enhancer Browser(Visel, Minovitsky, Dubchak, & Pennacchio, 2007) consists 
of 2194 such experimentally validated mouse and human candidate enhancer 
segments, 1154 (53%) of which tested positive in at least one mouse embryonic 
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tissue. This provided a rich source to train machine learning algorithms on 
various features and make corresponding predictions for novel enhancers.  
We present a supervised-learning-based pipeline that integrates many features 
across different developmental stages to predict tissue-specific enhancers with 
high accuracy. We scored multiple histone modification features from mouse 
embryonic heart, forebrain, midbrain, hindbrain, neural tube and limb, across 
developmental time points against the VISTA intervals to train our models, which 
we then aggregated. The performance of our classifier was measured in terms of 
area under ROC curve and was in the range of 0.75-0.89 for six tissues—heart, 
forebrain, midbrain, hindbrain, limb and neural tube. Upon examining correlations 
of auROCs across tissues using only sequence k-mers as features, we find that 
tissues that share developmental paths are correlated in predictability. This 
finding matched well with our exploratory analysis of the in vivo tested intervals, 
wherein we found that out of 258 intervals that exhibited enhancer activity in 
exactly two tissues, the pairs of tissues with highest frequencies were those of 
tissues that were closely related in embryonic developmental pathways. 
 
Results 
The VISTA enhancer database comprised 2192 elements, 1154 of which tested 
positive for enhancer activity in at least one tissue. 1740(79%) of the in vivo 
tested intervals were human intervals and the rest were mouse intervals. Our 
training set, composed of mouse intervals as well as mouse orthologs of the 
  
54 
human segments, consisted of 2179 elements. In order to have our algorithm to 
predict tissue-specific enhancers, we labeled the intervals in the training set such 
that enhancer intervals that were positive in the tissue of interest were labeled as 
positive, whereas all other assayed intervals were labeled as negative - 
regardless of whether they were positive in other tissues or negative for all 
tissues. To account for variation in the training examples, we implemented a 
bootstrap aggregation(“bagging”) strategy to account for variability in the training 
set. We integrated histone modifications, DNase hypersensitivity, P300 and 
CAGE experiments performed across multiple mouse embryonic developmental 
time points to train our models.  
We plotted the Receiver Operating Characteristic (ROC) curve for each tissue 
and measured classifier performance as area under the ROC curve for an test 
set, which contained a randomly selected group of 20% of the in vivo assayed 
intervals. The ROC curves are shown in Figure 11 for heart, forebrain and limb 
tissues.  
We then repeated this procedure for 30 iterations of randomly selected test sets 
and plotted the distributions of auROCs for each tissue (Figure 12). The median 
auROC for the six tissues ranged from 0.75 for hindbrain to 0.88 for heart. 
Additionally, we were also able to assess the importance of each feature as part 
of the random forest classification (see methods for details). We found that for 
prediction of enhancers in all tissues, P300 binding and H3K27ac enrichment 
were most important, closely followed by DNase hypersensitivity. The top 25 
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most influential variables for heart and forebrain predictions are shown in figure 
14. 
 
Figure 11. ROC curves to assess classifier performance for heart, forebrain and 
limb tissues.  
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Figure 12. Distributions of auROCs for enhancer classifier performance for six 
tissues, each point in the distribution corresponds to a different test set, randomly 
chosen from the in vivo tested intervals 
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Figure 13. Variable importance of most informative predictors of enhancer activity 
for (a) heart and (b) forebrain, measured in units of mean decrease in Gini 
impurity scores 
 
Figure 14. Heatmap of Pearson correlation coefficients between auROCs 
computed by modeling enhancers only by k-mer content. 
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Next, we proceeded to investigate the influence of sequence features on 
enhancer identity. We compiled 2147 TF-binding motifs across JASPAR and 
TRANSFAC databases, and from our previous work(J. Wang et al., 2012) and 
used FIMO(Grant, Bailey, & Noble, 2011) to find matching sequences on the VISTA 
intervals. We found that neither densities (number of motif matches per base) nor 
match scores of 1422 TRANSFAC motifs were able to classify enhancers. We 
then modified our search to include 2772 k-mers of length 1-6 (all combinations 
of nucleotide sequences of lengths 1 to 5, minus their reverse complements) to 
identify discriminative sequences. We scored the occurrence of each k-mer as a 
percentile over its occurrence in a matched background and used these scores 
to train our model. In this integrative sequence-based training, the highest 
performance we observed was for classifying heart enhancers, with an auROC of  
In parallel, we also measured the predictive capacity of each individual k-mer by 
using only its percentile enrichment over background, to derive true and false 
positive rates for each score threshold, and thus deriving an auROC for each k-
mer. We performed this analysis for VISTA enhancers active in only one tissue to 
rule out the duplicative effects of enhancers shared across multiple tissues. We 
found that k-mers shared their predictive capacity between related tissues—that 
is, if a k-mer had a high predictive capacity in forebrain (as measured by its 
auROC), it was also likely to predict midbrain tissues with high auROC. When we 
correlated these auROCs for the six tissues we analyzed, we found that brain 
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tissues clustered together and heart showed the least correlation in predictability 
with all the other tissues, as shown in figure 14. 
 
Discussion 
Identification of transcriptional enhancers is crucial and at the same time 
challenging owing to a lack of an apparent relationship with the genes that they 
regulate. However, they have been associated with many epigenomic features 
such as certain activating histone modifications(Heintzman et al., 2009), 
accessible DNA, enrichment of the acetylase P300(Visel et al., 2009) and 
evidence of transcriptional activity(T.-K. Kim et al., 2010). Thus far, these 
features have been evaluated independently in their capability to identify 
enhancers and have had good accuracies in their predictions. 
In this study, we integrated multiple genomic and epigenomic features generated 
from mouse embryonic tissues across various developmental stages in a 
supervised learning method to accurately predict enhancers in a tissue-specific 
manner. Specifically, we used ChIP-seq assays for histone modifications 
H3K27ac, H3K9ac, H3K4me1/2/3, H3K36me3, H3K27me3 and H3K9me3 
performed across embryonic days 11.5, 14.5, 16.5 and postnatal day 0 in various 
tissues. Additionally, we used sequence information such as match scores of 
~2000 motifs as well as enrichment of 1-6mers. As a training set, we used 
human and mouse intervals tested in vivo for enhancer activity, maintained in the 
VISTA enhancer database(Visel et al., 2007). Our method accounted for 
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variability in training data by bootstrapping and aggregating scores across the 
bootstraps. Classifier accuracy was evaluated as area under ROC curve 
(auROC). The auROC was highest for heart classification (0.88) and lowest for 
hindbrain (0.75). We also ranked predictor variables in terms of their importance. 
As seen in Figure 13, for heart and forebrain enhancer predictions, H3K27ac, 
DNase accessibility and H3K4me1 were among the top-ranked variables. 
Acetylation of H3K27 has been implicated in enhancer activity in numerous 
studies(Görisch et al., 2005; Heintzman et al., 2009) (Lee et al., 1993; Struhl, 
1998) in that they contribute to the unwinding of DNA from the histone core, thus 
exposing potential binding sites for transcription factors to bind, in order for 
transcriptional activation to ensue. P300 is an acetylase that has been strongly 
associated with enhancer activity in a tissue-specific manner (Visel et al., 2009). 
Mono-methylation of H3K4, another top-ranking predictor in our analysis is 
associated with marking poised enhancers in embryonic tissues(Creyghton et al., 
n.d.), as well maintaining enhancers in a latent state, ready for quicker activation 
in immune cells(Ostuni et al., 2013). 
Although multiple methods have been proposed to identify transcriptional 
enhancers, ours is unique in that it integrates a wide variety of features and uses 
an in vivo validation system to train and test accuracies in a tissue-specific 
manner. The algorithm is generic and easily scalable to changes in variables and 
size of training data. As more experimental data become available, we hope to 
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incorporate them into the prediction algorithm to learn more about the biology of 
enhancers. 
Methods 
Out of the pool of 2154 training examples, we created 10 bootstraps (random 
sampling with replacement) and added the ranks of prediction scores from all 
bootstrapping sets as the “score” or measure of confidence for the prediction. We 
then tested this ensemble score against a fixed test set using many classifiers. 
We repeated this algorithm 30 times for each tissue, for 30 different test sets, 
with each iteration yielding a different auROC for each classifier.  
The set of in vivo tested enhancers (human and mouse intervals) were obtained 
from http://enhancer.lbl.gov. As of the date of this writing, there were 2192 tested 
intervals, with 1154 elements testing positive for enhancer activity in at least one 
tissue. 
Scoring for histone modification features: If the interval intersects a histone 
modification peak, the sum of scores of the intersections (weighted by the 
number of intersecting bases) is assigned as the score. If the interval does not 
intersect a peak, the overall signal over the entire training interval is assigned as 
the score.  
Scoring for motif matches: We used FIMO with the following parameters to 
search for matches to 2147 motifs across the JASPAR, Transfac and factorbook 
motif databases.  
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fimo --oc $HOME/enhancer.fimo_out --verbosity 2 --qv-thresh --thresh 0.1 
JASPAR_transfac_zlab.meme enhancer_predictions.fa 
Scoring for kmer features: For each of the 2772 kmers, the number of motifs per 
base was calculated as a percentile over a random background and assigned as 
the feature score for that kmer. 
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5. HIGH-THROUGHPUT SEQUENCING ANALYSIS OF POST-LIVER 
TRANSPLANTATION HCV E2 GLYCOPROTEIN EVOLUTION IN THE 
PRESENCE AND ABSENCE OF NEUTRALIZING MONOCLONAL ANTIBODY2  
 
Introduction 
Chronic hepatitis C virus (HCV) infection is the most common cause of end-stage 
liver disease leading to liver transplantation in the United States(W. R. Kim et al., 
2012). Unfortunately, recurrence of hepatitis C infection post-transplantation is 
nearly universal. While serum HCV RNA levels initially decline with removal of 
the infected liver, circulating virions infect the donor liver within hours and viral 
concentrations increase rapidly in most patients, often exceeding pre-transplant 
levels(Garcia-Retortillo, 2002; Powers et al., 2006). Recurrent HCV disease is often 
more aggressive in the setting of post-transplant immunosuppression, with 
accelerated cirrhosis, increased risk of graft failure, and death(Crespo, Mariño, 
Navasa, & Forns, 2012; Gallegos-Orozco et al., 2009). 
MBL-HCV1 is a novel fully human IgG1/kappa monoclonal antibody (MAb) 
                                            
2 Gregory J. Babcock*, Sowmya Iyer*, Heidi L. Smith*, Yang Wang, Kirk Rowley, 
Donna M. Ambrosino, Phillip D. Zamore, Brian G. Pierce, Deborah C. Molrine, 
Zhiping Weng 
High-throughput sequencing analysis of post-liver transplantation HCV E2 
glycoprotein evolution in the presence and absence of neutralizing monoclonal 
antibody 
PLoS ONE 9(6): e100325. doi:10.1371/journal.pone.0100325 
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isolated from mice expressing human antibody genes (Medarex, Inc., a wholly 
owned subsidiary of Bristol-Myers Squibb). MBL-HCV1 binds a highly-conserved 
linear epitope of the HCV E2 envelope glycoprotein (amino acids 412–423) and 
neutralizes a broad range of genotypes in vitro(Broering et al., 2009; Gallegos-
Orozco et al., 2009). MBL-HCV1 is capable of preventing HCV infection in a 
chimpanzee model of acute HCV(Morin et al., 2012). Treatment of chronically-
infected chimpanzees with a single dose of MBL-HCV1 led to suppression of viral 
load in a subset of animals for up to 14 days, with viral rebound coinciding with 
the emergence of antibody-resistant virus. Alterations at amino acid positions 
415 (N415K and N415D) and 417 (N417S) within the MBL-HCV1 epitope 
dominated the viral population in chimpanzees post-treatment(Morin et al., 2012). 
The ability of MBL-HCV1 to prevent HCV recurrence after liver transplantation is 
being investigated in clinical trials as current treatment options are limited. In a 
phase 2 randomized, placebo-controlled trial in this target population, treatment 
with MBL-HCV1 significantly delayed median time to viral rebound compared to 
placebo treatment(Chung et al., 2013). The strong selective pressure of this 
neutralizing antibody resulted in the emergence of MBL-HCV1 resistance-
associated variants (RAVs), as determined by conventional cloning and Sanger 
sequencing methods in all subjects receiving MAb monotherapy. The time to 
emergence of detectable RAVs varied from 6 to 42 days and was associated with 
a rebound in circulating viral titer. 
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In this article, we use high-throughput next generation sequencing to investigate 
the presence of resistance mutations to MAb pre-transplant and examine the 
post-transplant evolution of HCV variants in the presence and absence of MBL-
HCV1 antibody (SRA study accession number SRP037575). 
Results 
Analysis of HCV E1/E2 Variants at Time of Viral Rebound 
Eleven enrolled subjects underwent liver transplantation in a phase 2 clinical 
study(Table 1)(Chung et al., 2013). Six subjects were randomized to receive MBL-
HCV1 (subjects A–F) and five subjects were randomized to placebo (subjects G–
K). To assess viral RNA sequences found in serum samples obtained during the 
clinical study, a high-throughput sequencing methodology was developed. We 
initially applied high-throughput next generation sequencing to samples obtained 
following 2 log10 viral rebound in MBL-HCV1-treated subjects. For placebo 
subjects, samples obtained 7–21 days post-transplantation were also 
sequenced. The frequencies of amino acid alterations at the positions associated 
with resistance to MBL-HCV1 neutralization were analyzed (Table 1). 
Three of the MAb-treated subjects (Subjects A, B, and C) experienced viral 
rebound of at least 2 log10 IU/ml by day 14 post-transplantation (Figure 15 A-C) 
Subject A displayed a mixture of N415D (78.5%) and N417S (20.5%) as the 
predominant viral strains at the time of rebound. The rebounding population 
found in subject B was dominated by the variant N415K (97.1%). Subject C had 
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a greater diversity at positions 415 and 417 than Subjects A or B at day 14, with 
N415D (56.0%), N415K (2.6%), and N417S (12.7%) mixing with quasispecies 
possessing wild-type epitope sequence (25.8%). 
Three of the MAb-treated subjects experienced viral rebound significantly later 
than day 14 (Figure 15 D-F) Subject D demonstrated the greatest suppression of 
HCV viremia following MBL-HCV1 treatment. This subject's viral load transiently 
fell below the limit of detection and remained below the lower limit of 
quantification of the HCV RNA assay through day 28. Viral load rebounded 2 
log10 IU/ml by day 42; however deep sequencing of this serum sample failed for 
technical reasons. Deep sequencing of the day 56 sample revealed a 
predominance of the N417S variant (78.4%) and N415K (20.2%). Surprisingly, 
these two variants were never detected in the same sequence read, indicating 
that either variant was sufficient for viral escape. For subject E, a post-rebound 
viral sample obtained on day 28 following transplantation revealed a 
predominance of N415K (94.2%). Subject F did not experience a 2 log10 IU/ml 
viral rebound until approximately 42 days post-transplantation and maintained 
wild-type virus (N415/N417) at 34% at this time point. Resistance-associated 
mutations N415S (27.1%), N415D (1.2%) and N417S (36.5%) were detected by 
high-throughput sequencing. A previous ad hoc analysis of the clinical data from 
the pharmacokinetic analysis showed no correlation between the serum antibody 
concentration and the time to viral rebound (data not shown). 
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For four of the five placebo-treated subjects (Subjects G-K), high-throughput 
sequencing yielded wild type N415/N417 sequences at a frequency of >95% 
(Table 1, Figure 16) Interestingly, subject J had a naturally occurring N417S 
variant that dominated the viral population both pre- and post-transplantation and 
demonstrated a unique pattern of viral rebound compared to the other placebo 
subjects. Subject J did not rebound to viral titers ≥10,000 IU/ml post-transplant, 
limiting the ability to analyze post-transplant sequencing results in this subject. 
Subject J did not have detectable circulating antibodies to the 412–423 epitope. 
Pre-Transplant Prevalence of Sequence Variation at Amino Acids 415 and 
417 
With the emergence of four different viral variants following treatment with MBL-
HCV1 (N415K, N415D, N415S and N417S), we next determined whether these 
variants were present before transplantation in any of the 11 subjects. High-
throughput sequencing was performed on pre-transplantation serum samples 
from all subjects. None of the MBL-HCV1-treated subjects (Subjects A–F) had 
resistance-associated variants (Figure 15) present above the detection threshold 
specified for each sample (Table 1) pre-transplantation. Each placebo subject 
(Subjects G-K) maintained the exact same amino acids at positions 415 and 417 
E2 post-transplantation as they had exhibited pre-transplantation (Table 1, Figure 
16), suggesting that these positions are not under selective pressure as the viral 
quasispecies adapt to the newly transplanted liver. 
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Subject	   Treatment	   Baseline	  IU/ml	  (log10)	  
Study	   day	  sequenced	  post-­‐viral	  rebound	  
Estimated	  number	   of	  input	  genomes	  	  
Position	  415	   amino	  acid	  (%)	  
Position	  417	  amino	  acid	  (%)	  
A	   MBL-­‐HCV1	   6.7	   14	   2,664,824	   D	  (78.5)	   N	  (78.8)	  
	   	   	   	   	   N	  (20.8)	   S	  (20.5)	  
B	   MBL-­‐HCV1	   6.1	   14	   27,214	   K	  (97.1)	   N	  (99.0)	  
	   	   	   	   	   N	  (1.7)	   	  
C	   MBL-­‐HCV1	   7.2	   14	   32,037	   D	  (56.0)	   N	  (85.6)	  
	   	   	   	   	   N	  (39.7)	   S	  (12.7)	  
	   	   	   	   	   K	  (2.6)	   	  
D	   MBL-­‐HCV1	   4.5	   56	   48,210	   N	  (78.8)	   S	  (78.4)	  
	   	   	   	   	   K	  (20.2)	   N	  (21.1)	  
E	   MBL-­‐HCV1	   6.0	   28	   32,196	   K	  (94.2)	   N	  (97.9)	  
	   	   	   	   	   N	  (2.7)	   	  
F	   MBL-­‐HCV1	   6.1	   42	   251,910	   N	  (69.5)	   N	  (61.5)	  
	   	   	   	   	   S	  (27.1)	   S	  (36.5)	  
	   	   	   	   	   D	  (1.2)	   	  
G	   Placebo	   6.6	   7	   1,698,789	   N	  (99.1)	   N	  (98.8)	  
H	   Placebo	   5.5	   7	   25,752	   N	  (95.9)	   N	  (96.7)	  
I	   Placebo	   6.0	   21	   575,572	   N	  (98.6)	   N	  (99.1)	  
J	   Placebo	   5.1	   21*	   56	   N	  (99.0)	   S	  (98.7)	  
K	   Placebo	   5.6	   7	   2,434,095	   N	  (98.9)	   N	  (99.3)	  
  
69 
Table 1. Subject characteristics and resistance-associated variants at viral  
rebound.  
 
Evolution of resistance-associated variants 
Since daily serum samples were available for analysis from the first week post-
transplantation, high-throughput sequencing was performed on serum samples 
obtained on Day 4 and Day 7 post-transplantation from the three MBL-HCV1- 
treated subjects with viral rebound occurring between days 7–14 (Subjects A, B, 
and C) to explore the evolution of resistance-associated variants. The amount of 
template in these samples was limited by the low viral load at these early time 
points (Figure 15 A-C) ranging from 1,010 IU/ml (Subject B, Day 7) to a 
maximum of 10,357 IU/ml (Subject C, Day 4). On Day 4 post-transplantation, 
none of the subjects had detectable levels of variants associated with resistance 
to MBL-HCV1. By Day 7 post-transplant, neither Subject B nor Subject C had 
detectable 415 or 417 variants, but Subject A had a dominant population of RAVs 
(a mixture of N415D and N417S) (data not shown). High-throughput sequencing 
of additional samples obtained from Subject A during the first post-transplant 
week revealed detectable resistance-associated variants on Day 3 (N417S, 
6.9%), but not on Day 4 or Day 5 (data not shown). By Day 6, however, 
resistance associated variants (N415D 26.5% and N417S 53.7%) predominated 
the viral pool, even before the viral load had appreciably increased in this 
subject). 
Given the limited amount of starting template in serum samples from MAb-
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treated subjects in the first week post-transplant, multiple samples with viral titers 
<3, 000 IU/ml were sequenced a second time to assess the reproducibility of 
these results. For subject A when library DNA from the Day 3 sample (1,930 
IU/ml), in which low-level RAV (N417S) were detected in the initial analysis, was 
recreated with the same sets of primers and re-sequenced, the N417S 
resistance-associated variant was no longer detected. For the Day 4 sample 
(1,213 IU/ml), E1/E2 DNA sequences were amplified from the original RNA 
preparation, subjected to 2 additional rounds of re-amplification with subject-
specific primers, and sequenced. This technique resulted in the detection of 2 
resistance-associated variants that predominated the eventual viral rebound: 
N415D (1.9%) and N417S (17.4%). The Day 5 sample was extracted from a new 
aliquot of serum from that time point and amplified using the same techniques as 
the original Day 5 sample. The repeat of sequencing from this time point 
revealed N415D (13.9%) and N417S (2.8%) resistance-associated variants that 
were not detected in the original sequencing run. Finally, re-extraction of RNA 
and re-sequencing of the Day 6 time point yielded the same resistance 
associated variants as the prior run, but at significantly lower frequencies 
compared with the previous sequencing run (N415D 16.2% vs. 26.5% and 
N417S 19.0% vs. 53.7%). 
These inconsistencies were also observed when low titer samples from a second 
subject were re-sequenced. For Subject B, the Day 4 sample (2,704 IU/ml) was 
amplified from the same RNA preparation and analyzed by high throughput 
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sequencing. Interestingly, there were detectable levels of N415K (7.82%), the 
variant that eventually dominated the viral population at the time of rebound, 
when this Day 4 sample was re-sequenced. However, when the RNA from the 
Day 7 sample (1,010 IU/ml) from the same subject (Subject B) was re-extracted, 
amplified, and re-sequenced, there were no detectable 415 or 417 variants. 
These findings demonstrate the limitations in the reproducibility of detecting low-
level variants contained within low-titer samples. 
When serum samples with titers >10,000 IU/ml were subjected to repeat 
sequencing however, the results were quite reproducible. For example, subject A 
had a post-rebound viral titer of 35,530,988 IU/ml on Day 14 after transplantation. 
Two independent amplification and sequencing runs yielded a frequencies of 
78.53–83.37% for the N415D variant and 15.54–20.47% for the N417S variant. 
Sequence evolution within the MBL-HCV1 epitope 
Having analyzed positions 415 and 417, we also interrogated the entire MBL-
HCV1 epitope (amino acids 412–423) to assess whether there were 
combinations of positions that likely contribute to resistance. We analyzed the 
sequencing reads that covered the entire epitope and identified the most 
abundant epitope sequences in each sample. The frequency of each epitope 
sequence above the detection limit is illustrated in Figure 15. 
Consistent with the high conservation of this epitope, a majority of reads 
translated to the sequence QLINTNGSWHIN on day 0 pre-transplantation in four 
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of six MAb-treated subjects (89.0%, 87.8%, 90.8% and 84.4% for patients B, C, 
E and F, respectively). Two of the MAb-treated subjects had a high frequency of 
the I414V variant of this canonical sequence (26.2% in subject A and 91.3% in 
subject D). By the day of viral rebound, the pre-transplant dominant epitope 
sequence dramatically declined in all MAb-treated subjects. For four MAb-treated 
subjects (A, B, D, and E), the epitope sequence that dominated pre-transplant 
was below the detection threshold on the day of rebound. For subjects C and F, 
the prevalence of the wild-type sequence dropped to 24.8% and 34.6% 
respectively. 
The MAb-resistant epitope sequences contained only point mutations at positions 
415 or 417 with respect to the dominant sequences pre-transplantation and all of 
the resistant variants were obtained by mutating a single nucleotide. The most 
abundant MAb-resistant variant differed among the subjects (I414V; N415D for 
subject A, N415K for subjects B and E, N415D for subject C, I414V; N417S for 
subject D, and N417S for subject F;Figure 15). Nonetheless, a glycosylation site 
is maintained in the variant, with the “N-X-S” motif starting at either positions 415 
or 417 (Figure 15 G). A mutation at position 415 (from unglycosylated N to D, K, 
S, or glycosylated N) appears required for evasion of MBL-HCV1 neutralization. 
In comparison, none of these MAb-resistant epitope sequences emerged post-
transplant in the subjects treated with placebo (Figure 16). 
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Sequence evolution outside the MBL-HCV1 epitope 
We then expanded our analysis outside the MBL-HCV1 epitope by scanning the 
entire length of the deeply-sequenced E1/E2 regions to identify other amino acid 
positions that may be subject to selective pressure in MAb-treated subjects 
compared to placebo treated subjects. For each position, we performed a chi-
square test to quantify the change in the amino-acid distributions between day 0 
and the day of rebound, using the day 0 distribution as the expected frequencies 
and the distribution at rebound as the observed frequencies. A larger chi-square 
value would therefore correspond to a greater deviation from the day 0 
distribution. 
We performed this analysis on all 621 sequenced positions across 6 MBL-HCV1-
treated and 4 placebo-treated subjects; subject J in the placebo group could not 
be analyzed due to low post-rebound viral titers (<10,000 IU/ml). The degree of 
variation at each amino acid position post-viral rebound was ranked by 
comparing the difference in the average chi-square values among the MAb-
treated subjects and the average chi-square values among the placebo-treated 
subjects. The heatmap in Figure 17 shows the normalized variations (absolute 
difference between each position's chi-square statistic value and the median chi-
square value across all positions for the patient) for the 15 most significant amino 
acid positions. Owing to very high coverage and the sensitivity of this method to 
coverage, we found that many positions changed significantly between day 0 and 
the day of rebound. However, the difference in average magnitudes of the amino 
  
74 
acid variation between MAb- and placebo-treated subjects at position 415 was 10 
times higher than the next highest position, 417 (Figure 17), which highlights the 
importance of position 415 in antibody evasion. Moreover, the heatmap shows 
that positions 415 and 417 are highly significant across all six MAb-treated 
subjects and the other positions were only highly significant among subsets of 
patients. Changes at these other positions co-occur with alterations at position 
417 in a subset of MAb-treated subjects (A and D) and could either interfere with 
MBL-HCV1 binding through an indirect or allosteric effect or could potentially 
represent compensatory changes which enhance infectivity of the RAVs. Given 
that the N417S mutation confers full resistance to MBL-HCV1 
neutralization(Morin et al., 2012), it is unlikely that mutations outside of the MBL-
HCV1 epitope in conjunction with N417S provide additional resistance to 
neutralization. These changes may enhance fitness of the N417S variant or they 
may be fortuitous. 
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Figure 15: Changes in viral loads and epitope sequence distributions upon MBL-
HCV1 antibody administration. (A)-(F) represent epitope distributions for subjects 
A, B, C, D, E and F respectively. X axis represents time point in days, 0 denoting 
pre-transplant baseline sample. Note the depletion of wild-type sequence in all 
patients and the emergence of resistant epitope sequences (see proportions in 
left Y axis), in conjunction with viral rebound (right Y axis). Positions 415 and 417 
are highlighted in blue in the legend. (G) Summary of antibody-resistant 
mutations in epitope sequences, assuming maximum parsimony. Glycosylation 
motifs are highlighted in orange. 
 
Figure 16.  Changes in viral loads and epitope sequence distributions in placebo 
subjects. (A)-(E) represent epitope distributions for subjects G, H, I, J and K 
respectively. X axis represents time point in days, 0 denoting pre-transplant 
baseline sample. Left Y axis represents proportion of reads with a particular 
sequence and right Y axis represents viral loads across time points (X axis). 
Subject J did not have viral titers > 10,000 IU/ml by day 21; therefore analysis of 
post-transplant epitope sequence distributions could not be performed. 
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Figure 17: Positions in E1/E2 sequence that show the most significant changes 
in response to antibody treatment. Left: Median-shifted chi-square statistic values 
of the top 15 amino acid positions across E1 and E2 that show the most 
difference in average chi-square statistic between MBL-HCV1- and placebo-
treated subjects. Placebo subject J was unable to be analyzed due to post-
rebound viral titers < 10,000 IU/ml.  The chi-square statistic quantifies changes in 
amino acid distributions between day 0 and day of rebound for each subject in 
each position across the genome. A higher statistic represents a larger change in 
the amino acid distribution (darker red in heatmap). Positions labeled in green 
are those within the MBL-HCV1 epitope. Positions labeled in blue are known to 
participate in CD81 binding. Positions in pink belong to the E1 sequence. Right: 
Differences in mean chi-square statistic between MBL-HCV1-treated and 
placebo patients. Note that change in position 415 is most significant being 10-
fold higher than the second-ranked position 417. 
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The recently published crystal structure of the HCV E2 core [9] permitted us to 
examine these positions in greater detail with respect to the MBL-HCV1 epitope 
and the tertiary structure of E2 (Table 2). All of the positions were relatively 
distant (>18 Å) from residues 421–423 of the epitope (residues 412–420 were 
disordered in the E2 core structure), and on the opposite side of the E2 core, 
confirming as noted above that impact on MAb binding, if any, would not be via 
direct interference. Though they have varying degrees of surface exposure in the 
E2 core structure, the relatively conservative nature of the amino acid changes 
before and after MAb treatment, as well as the lack of E1 and remainder of the 
E2 protein in the structure, makes their functional importance in the context of 
MAb resistance difficult to assess without additional data. 
Position Amino acid Side chain % 
ASA 
Distance from 
MBL-HCV1 
epitope (Å) 
Amino acid 
change 
603 I 2.1 23.8 I è L 
563 V 31.1 21.0 V èA 
624 Y 20.6 26.2 Y è F 
618 Y 7.4 20.2 Y è F 
558 T 61.3 18.2 T è S 
434 N 77.1 23.9 Kè N 
     
Table 2. Significant amino acid changes outside of the MBL-HCV1 epitope and 
their physical distance from the MBL-HCV1 epitope based on the E2 core 
structure. 
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Discussion 
Treatment at the time of liver transplantation presents a potential opportunity for 
clearance of hepatitis C infection, given that the primary source of infectious 
virions is the patient's infected liver(Powers et al., 2006). Nearly all HCV-infected 
patients experience a substantial drop in circulating viral load at the time the 
diseased liver is removed, only to have viral titers increase rapidly as the donor 
liver becomes productively infected(Garcia-Retortillo, 2002; Powers et al., 2006). An 
immunoprophylactic strategy to neutralize circulating virions with HCV-specific 
antibody therapy could exploit this opportunity and protect the allograft in the 
peri-transplantation period. Human monoclonal antibody MBL-HCV1 provided 
potent suppression and selective pressure on HCV during the early post-
transplant period in a randomized, placebo-controlled trial(Chung et al., 2013). 
Viral load was suppressed in 6 of 6 MAb-treated subjects for time periods 
ranging from 7 to 28 days, though the virus eventually rebounded with a 
population dominated by variants with alterations at positions 415 or 417 of the 
E2 envelope glycoprotein determined by Sanger sequencing(Chung et al., 2013). 
Alterations at these positions have previously been shown to be the main 
route(s) of escape from MBL-HCV1 neutralization in vitro(Broering et al., 2009) as 
well as in vivo in chimpanzees(Morin et al., 2012). 
We developed a high-throughput sequencing methodology to improve the 
sensitivity to detect low frequency viral strains and further investigate the 
presence of MAb resistance-associated variants before transplant as well as the 
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development of MAb-escape variants in the peri-transplant and early post-
transplant period. Evaluation of rebounding virus load by high-throughput 
sequencing in MAb-treated subjects identified the same population of escape 
variants as seen by Sanger sequencing for 5 of the 6 MAb-treated 
subjects(Chung et al., 2013). For Subject C, only high-throughput sequencing 
detected the N417S variant at 12.7% on day 14, the earliest day rebound was 
detected. This variant later dominated the viral population when a sample from 
Day 56 was subject to Sanger sequencing. 
High-throughput sequencing was also used to evaluate the pre-transplant viral 
population in the study subjects. Sanger sequencing of pre-treatment serum 
samples from subjects in the MAb cohort did not detect any of the resistance-
associated variants present at the time of viral rebound(Chung et al., 2013). There 
was a single subject in the placebo group (Subject J) whose dominant viral 
species was an N417S epitope variant, both pre- and post-transplant. With a 
sensitivity threshold of 0.5–3.5%, we were unable to detect any additional MAb-
resistance associated variants before transplantation. In studies of drugs 
inhibiting the HCV NS3 protease, the frequency of patients with pre-existing NS3 
resistance associated variants was 12% by deep sequencing (0.25% assay 
cutoff) and 3.5% by Sanger sequencing (20% cutoff)(Bartels et al., 2013; 
Svarovskaia, Martin, McHutchison, Miller, & Mo, 2012). However, when treated with 
telaprevir in combination with interferon-α and ribavirin, individuals with 
resistance-associated variants detectable at baseline by Sanger sequencing had 
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similar rates of sustained virologic response as individuals without detectable 
baseline resistance-associated variants(Bartels et al., 2013). As resistance-
associated variants to MBL-HCV1 were not detectable in MAb-treated subjects 
prior to therapy, we are unable to evaluate the virologic response in subjects with 
pre-existing variation in E1/E2 that could potentially impact neutralization. Given 
the time required for three of the six subjects to present with viral rebound (>14 
days), either RAV were not present in the viral population at the time of treatment 
or any RAV present prior to treatment required additional mutations to acquire 
replication fitness in at a minimum these three treated subjects. Given the rapid 
replication rate of the Hepatitis C virus within in the host, it is unlikely that the 
differences in time to viral rebound observed within the MAb cohort were a result 
of varying levels of pre-existing resistance-associated variants prior to 
transplantation. 
We attempted to evaluate the evolution of the viral population in the early post-
transplant period; however, our evaluations were severely limited by the low HCV 
viral load in these samples. This effect was most pronounced in the MAb-treated 
group, where serum samples with HCV RNA concentrations <1000 IU/ml were 
unable to be successfully amplified. In addition, the biologic reproducibility of 
sequencing results from samples containing HCV RNA serum titers between 
1000–10,000 IU/ml was poor. Although deep sequencing significantly increases 
the sensitivity and resolution of sequencing in clinical samples, the ability to draw 
conclusions from samples with low viral concentrations remains limited by the 
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starting amount of viral template. In low titer samples, each viral template 
constitutes a larger percentage of the total sample and small variations in 
amplification efficiency can yield marked changes in final frequency. 
All of the MBL-HCV1-treated subjects had an alteration at amino acid positions 
415 (N415D, N415K, N415S) or 417 (N417S) of the E2 glycoprotein at the time 
of post-transplant viral rebound. Sequence analysis of the 412–423 epitope in its 
entirety revealed that the 415 and 417 changes were never observed in the same 
virus. Interestingly, the N417S mutation mostly likely affected neutralization 
through its impact on position 415, by shifting the N-X-S glycosylation site to the 
asparagine at position 415. Recent in vitro studies have also confirmed this in 
vivo observation. Pantua et al.(Pantua et al., 2013) synthesized the N417S variant 
of E2, observed decreased ability to neutralize virus in vitro with epitope I-
directed antibodies, and confirmed glycosylation of the 415 asparagine by mass 
spectroscopy. The change at position 415 also appeared to be sufficient to 
confer resistance, in an otherwise replication competent virus, as there were no 
other sites on the E1/E2 glycoprotein that were consistently mutated at the time 
of rebound in multiple subjects. This is supported by the exposed “flap-like” 
structure of the MBL-HCV1 epitope(Kong et al., 2013)  that is apparently not 
embedded in the E2 core structure(Kong et al., 2012), reducing the likelihood of 
interaction with other residues at least within the main core structure (positions 
412–645). 
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There are both pre-clinical as well as emerging clinical evidence to suggest that 
addition of a second antiviral agent with a discrete mechanism of action can 
impair the development of resistance. The addition of the licensed HCV NS3 
protease inhibitor telaprevir to an antibody binding the E2 412–423 epitope in 
vitro led to a synergistic negative effect on viral replication and suppressed the 
emergence of resistance to both agents(Pantua et al., 2013). Given that the 
baseline frequency of HCV variants with resistance associated mutations in E2 
412–423 appears to be low and that post-transplant viral rebound is delayed until 
after day 7, antibody-based peri-transplant treatment could provide a safe, well-
tolerated therapy that can be started at the time of transplant surgery and allow a 
window of a few days for a small molecule antiviral agent targeting a different 
stage of the viral life cycle to be added once the patient has stabilized and graft 
function is established. Such combination therapy holds the potential to eliminate 
the hepatitis C virus before a chronic infection can be established in the newly 
transplanted liver. 
Materials and Methods 
Collection of Serum Samples for Viral Sequence Analyses  
Serum samples for HCV sequence analyses were obtained at protocol-specified 
timepoints as part of a randomized, double- blind, placebo-controlled trial of 
MBL-HCV1 treatment in liver transplant patients [8]. Eleven subjects with HCV 
genotype 1a infection were enrolled; six subjects received 11 study infusions of 
MBL-HCV1 (50 mg/kg each) and five subjects received 11 infusions of placebo 
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(0.9% sodium chloride, starting right before transplant surgery and continuing for 
14 days. Serum samples for assessment of HCV RNA titers and for viral 
sequence analyses were obtained prior to transplant, daily for the first post-
transplant week, and weekly through day 56 +/- 2 post-transplantation. Serum 
HCV RNA levels were measured at ICON Central Laboratories (Farmingdale, 
NY) using the COBAS Ampliprep/COBAS Taq- Man HCV Test (Roche Molecular 
Diagnostics) as previously described [8].  
E1/E2 Amplification and High-throughput Sequencing  
Viral RNA was extracted from 1 ml of human sera using the QIAamp viral RNA 
mini kit (Qiagen) as described by the manufacturer to a final volume of 240 
microliters. Three microliters of viral RNA in six independent reactions for each 
sample was amplified using the Superscript III One-Step RT-PCR system with 
Platinum Taq (Invitrogen). For specific amplification, a forward oligonucleotide 
containing a HindIII restriction site (59- gct tag caa gct tCG CCG ACC TCA TGG 
GGT ACA TAC CGC TCG-39) targeting the gene encoding core, upstream of the 
E1 gene and a reverse oligonucleotide containing an XbaI restriction site (59-cgc 
ttg ctc tag aCG AGG TT CTC CAA AGC CGC CTC CGC TTG G-39) annealing to 
the 39 end of E2 were designed. RNA was reverse transcribed and DNA 
amplified for 30–40 cycles. RT-PCR resulted in an amplicon approximately 1890 
bp in size representing the entire E1/E2 coding region.  
For serum samples obtained at baseline or following 2 log10 viral rebound, the 
six independent reactions for each serum sample were pooled, resolved on 
  
86 
agarose gels and gel purified. A portion of the sample was cloned into pcDNA3.1 
using HindIII/XbaI and conventional Sanger sequencing was performed on 8–20 
unique clones. Approximately 1–5 micrograms of RT-PCR product was sheared 
using a Covaris S-series SonoLab Single sonicator to obtain DNA fragments 
near 225 bp in size. The 59 and 39 ends of the sheared DNA were repaired and 
blunted using the End-It DNA End-Repair Kit (Epicentre). Blunted DNA was A-
tailed using the Exo-minus Klenow kit (Epicentre). Illumina paired-end adapters 
containing 5-mer barcodes were ligated to the A-tailed DNA and the reaction 
products were resolved on 2% agarose gels. Adaptered material in the range of 
200–250 bp was gel purified and amplified (18 cycles) with Platinum Pfx 
(Invitrogen) and Illumina paired-end primers 1.01 and 2.01. Amplified material 
was purified using a QiaQuick PCR clean up kit (Qiagen). Purified material was 
assessed for concentration and library size distribu- tion using an Agilent 2100 
Bioanalyzer G2939A with the Agilent Bioanalyzer High Sensitivity DNA Kit.  For 
serum samples obtained prior to 2 log10 post-transplant viral rebound, a nested 
PCR was employed using subject-specific primers designed based on Sanger 
sequencing results of pre- transplant and post-rebound timepoints. Briefly, 
sequences upstream of the E1 gene were analyzed for each individual subject 
and a region with no nucleotide variability (pre-transplant or post-viral rebound) 
was selected for primer design. The reverse primer was the same as used in the 
One-Step RT-PCR and the forward primers were as follows: Subject A, 59-gct 
tag caa gct tGC TGC CAG GGC CCT GGC GCA TGG C-39; Subject B, 59-gct 
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tag caa gct tGG CGT CCG GGT TCT GGA AGA CGG CGT G-39; Subject C, 59-
gct tag caa gct tCC CTG GCG CAC GGC GTC CGG GTT C-39, Subject F, 59-
gct tag caa gct tCT GGC GCA TGG CGT CCG GGT CCT GG-39. Reamplified 
products were prepared for high-throughput sequencing as described above.  
High-Throughput Sequence Acquisition and Data Analysis  
All samples were sequenced using an Illumina HiSeq 2000 instrument to yield 
100-nucleotide paired-end reads. Table 1 provides detailed statistics on the 
sequencing datasets of all samples. Sequence quality was assessed using the 
FastQC software {http://www.bioinformatics.babraham.ac.uk/projects/fastqc/} and 
samples with inadequate quality were re-sequenced. In order to maintain 
comparable sequencing accuracies between samples, only reads with a quality 
score of 28 or higher for the first 50 bases were included in the analyses. These 
reads were mapped to a database of 581 E1/E2 HCV1 sequences obtained by 
Sanger sequencing from 27 HCV-infected individuals, including the 11 subjects 
in the current protocol. The BWA software(Li & Durbin, 2009) was used for read 
mapping, allowing a maximum of 5 mismatches per read. Datasets with an 
average fold-coverage of less than 40,000 reads per base were discarded. If 
multiple sequencing runs of the same sample passed the above criterion, the 
dataset with the greatest fold coverage was used for downstream analysis. 
Sequencing error for each dataset was estimated by computing the mean and 
standard deviation of error per base (percentage of reads with incorrect base 
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calls) in the invariant 3′-end primer region. The detection threshold for each 
sample was defined as the mean plus one standard deviation of the error rate, 
i.e., a nucleotide variant is considered to be present in a sample if its frequency is 
higher than the detection threshold. The sensitivity thresholds ranged from 0.5–
3.5% across the datasets (Table 3 below). 
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Subject	   Study	  day	   Treatment	   Viral	  titer	  
(IU/ml)	  
Total	  reads	   %	   reads	  
mapped	  
Mean	  	  
fold	  	  
coverage	  
(reads/base)	  
A	   0	   MBL-­‐HCV1	   5,496,127	   14,309,904	   41.92	   301,518	  
	   1	   	   5,822	   6,450,444	   79.71	   260,696	  
	   2	   	   3,296	   23,924,710	   80.08	   972,741	  
	   3	   	   1,930	   30,334,822	   78.89	   1,215,659	  
	   4	   	   1,213	   16,996,320	   64.63	   551,258	  
	   5	   	   1,065	   22,760,974	   80.28	   925,901	  
	   6	   	   1,163	   28,112,544	   70.69	   1,011,267	  
	   7	   	   1,820	   6,104,432	   66.62	   205,630	  
	   14	   	   35,530,988	   9,765,532	   47.41	   234,795	  
B	   0	   MBL-­‐HCV1	   1,135,133	   16,031,764	   37.53	   302,612	  
	   4	   	   2,704	   20,986,398	   68.63	   721,150	  
	   7	   	   1,010	   4,066,710	   62.67	   128,978	  
	   14	   	   362,858	   32,504,392	   68.74	   1,133,834	  
C	   0	   MBL-­‐HCV1	   15,423,018	   2,786,702	   33.45	   46,934	  
	   4	   	   10,357	   21,453,138	   55.81	   605,487	  
	   7	   	   6,880	   415,558	   70.13	   14,771	  
	   14	   	   427,166	   11,086,950	   48.58	   272,471	  
D	   0	   MBL-­‐HCV1	   29,616	   12,264,006	   49.68	   310,338	  
	   56	   	   642,797	   11,153,416	   47.76	   270,719	  
E	   0	   MBL-­‐HCV1	   989,109	   10,618,328	   50.60	   273,647	  
	   28	   	   429,279	   6,595,232	   27.15	   91,218	  
F	   0	   MBL-­‐HCV1	   1,207,945	   5,094,372	   35.86	   93,063	  
  
90 
	   4	   	   5,875	   17,530,674	   53.24	   474,167	  
	   28	   	   1,342	   27,525,394	   71.79	   1,006,162	  
	   35	   	   20,657	   19,969,004	   74.12	   753,599	  
	   42	   	   3,358,802	   4,143,238	   32.85	   69,326	  
G	   0	   Placebo	   3,786,170	   22,774,650	   52.75	   611,973	  
	   7	   	   22,650,518	   11,865,958	   58.16	   350,904	  
H	   0	   Placebo	   342,731	   22,030,844	   66.79	   746,145	  
	   7	   	   343,362	   22,710,172	   58.73	   677,817	  
I	   0	   Placebo	   1,083,060	   26,523,166	   51.69	   690,344	  
	   21	   	   7,674,293	   21,575,812	   51.68	   566,732	  
J	   0	   Placebo	   132,685	   20,094,210	   50.40	   515,376	  
	   21	   	   746	   19,675,784	   55.66	   557,882	  
K	   0	   Placebo	   386,586	   23,713,448	   44.32	   535,380	  
	   7	   	   32,454,598	   17,013,526	   28.21	   244,203	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tissues 
Research theme: Viral evolutionary genomics   
• Comparative analysis of HCV epitope sequences in Chimpanzees with 
chronic and acute infection   
• Predicted antibody-resistant loci in Hepatitis C Virus from viral sequences 
obtained from clinical  trial of HCV1 antibody administered to liver transplant 
patients  
o  Research Assistant to Dr. Charles Delisi, Boston University, Boston MA   
April 2009 – August 2009  • Comparative gene expression analysis in tumor 
(Breast cancer) and matched normal tissues using publicly available microarray 
data   
o Software Consultant (Citigroup Inc., Fidelity Investments)  Enterprise-level 
programmer for financial applications over the web 
January 1999 – January 2006  
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Skills 
·      R, Java, UNIX Shell scripting   
·      Computing in High Performance Clusters   
·     Analysis of NGS data   
·      Statistics and Machine learning   
  
Presentations 
13th Annual International Workshop on Bioinformatics and Systems Biology 
July 31 - August 2, 2013; Kyoto, Japan Analysis of Multiple Transcription Factor 
Occupancy in the Human Genome 
Poster and talk 
Awards 
• Outstanding employee award at Fidelity Investments August 2004   
• Multiple awards for Outstanding Contribution to various projects at Fidelity 
Investments (2003-  2005)   
• Dean’s list for Pre-medical Certificate Program in UMass Boston  Public 
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Service  Volunteered at the Multiple Sclerosis Clinic of Brigham and Women’s 
Hospital Brookline, MA (Mar 2006 – Nov 2006)   
 
 
